




The role of LEF1 and WNT signaling in 




for the award of the degree 
“Doctor rerum naturalium” 
of the Georg-August-Universität Göttingen 
 
within the doctoral program Molecular Biology of Cells 














Prof. Dr. Heidi Hahn 
Dept. of Human Genetics; University Medical Center Göttingen 
Prof. Dr. Holger Bastians 
Dept. of Molecular Oncology; Georg-August-University Göttingen 
Prof. Dr. Tobias Pukrop 
Dept. of Hematology/Medical Oncology; University Medical Center Göttingen  
Clinic for Internal Medicine III, Hematology and Medical Oncology; University 
Regensburg 
 
Members of the Examination Board 
Referee: Prof. Dr. Heidi Hahn 
Dept. of Human Genetics; University Medical Center Göttingen 
2nd Referee: Prof. Dr. Holger Bastians 
Dept. of Molecular Oncology; Georg-August-University Göttingen 
 
Further members of the Examination Board 
Prof. Dr. Matthias Dobbelstein  
Dept. of Molecular Oncology; Georg-August-University Göttingen 
Prof. Dr. Ralf Dressel 
Dept. of Cellular and Molecular Immunology; University Medical Center Göttingen  
Prof. Dr. Hubertus Jarry 
Dept. of Clinical and Experimental Endocrinology; University Medical Center Göttingen 
Prof. Dr. Ralph Kehlenbach 
Dept. of Molecular Biology; University Medical Center Göttingen 
 





I hereby declare that the PhD thesis entitled "The role of LEF1 and WNT signaling in 
growth and differentiation of rhabdomyosarcoma" has been written independently and with 


























Parts of this work have been published: 
Nitzki, F., Cuvelier, N., Dräger, J., Schneider, A., Braun, T., Hahn, H. (2016) 
Hedgehog/Patched-associated rhabdomyosarcoma formation from delta1-expressing 
mesodermal cells. Oncogene, 35(22) 
 
Parts of this work have been submitted for publication: 
Dräger, J., Simon-Keller, K., Pukrop, T., Klemm, F., Wilting, J., Sticht, C., Dittmann, K., 
Schulz, M., Leuschner, I., Marx, A., Hahn, H. (2016) LEF1 reduces tumor progression and 






Affidavit .............................................................................................................................. III 
Contents ............................................................................................................................... V 
List of Figures .................................................................................................................... IX 
List of Tables ....................................................................................................................... X 
1 Summary ................................................................................................................ 1 
2 Introduction ........................................................................................................... 3 
2.1 Rhabdomyosarcoma (RMS) .................................................................................... 3 
2.2 WNT signaling ........................................................................................................ 4 
2.2.1 β-catenin dependent (canonical) WNT signaling ............................................ 4 
2.2.2 Lymphoid enhancer factor 1 (LEF1) ............................................................... 6 
2.2.3 β-catenin independent (non-canonical) WNT signaling .................................. 7 
2.2.4 WNT5A signaling ........................................................................................... 9 
2.2.5 WNT signaling in RMS ................................................................................... 9 
3 Aim of the Study .................................................................................................. 11 
4 Material ................................................................................................................ 12 
4.1 Technical equipment.............................................................................................. 12 
4.2 Consumables .......................................................................................................... 14 
4.3 Reagents and chemicals ......................................................................................... 16 
4.4 Signaling pathway inhibitors ................................................................................. 18 
4.5 Kits and ready-to-use reaction systems ................................................................. 18 
4.6 Buffers and solutions ............................................................................................. 19 
4.7 Media ..................................................................................................................... 21 
4.7.1 Media and agar plates for culture of prokaryotic cells .................................. 21 
4.7.2 Media and reagents for culture of eukaryotic cells........................................ 21 
4.8 Biological material ................................................................................................ 22 
4.8.1 Bacterial strains ............................................................................................. 22 




4.8.3 Mouse lines .................................................................................................... 23 
4.8.4 Biopsies ......................................................................................................... 23 
4.9 Synthetic DNA-oligonucleotides ........................................................................... 23 
4.10 Synthetic RNA-oligonucleotides ........................................................................... 25 
4.11 Plasmids ................................................................................................................. 25 
4.12 Antibodies .............................................................................................................. 26 
4.13 Software ................................................................................................................. 27 
4.14 Databases ............................................................................................................... 28 
5 Methods ................................................................................................................ 29 
5.1 Molecular biology methods ................................................................................... 29 
5.1.1 Nucleic acid isolation .................................................................................... 29 
5.1.2 Photometric quantification of nucleic acids .................................................. 30 
5.1.3 Reverse transcription of RNA (cDNA synthesis) ......................................... 30 
5.1.4 Polymerase chain reaction (PCR) .................................................................. 31 
5.1.5 Agarose gel electrophoresis ........................................................................... 33 
5.1.6 Cloning techniques ........................................................................................ 33 
5.2 Cell biology methods ............................................................................................. 34 
5.2.1 Culture of eukaryotic cells ............................................................................. 34 
5.2.2 Cryopreservation of eukaryotic cells ............................................................. 35 
5.2.3 Retroviral transduction of eukaryotic cells .................................................... 35 
5.2.4 Transfection of eukaryotic cells .................................................................... 35 
5.2.5 Transient β-catenin knockdown (β-catenin KD) ........................................... 36 
5.2.6 TOP/FOP reporter assay ................................................................................ 36 
5.2.7 Dual-Luciferase assay.................................................................................... 36 
5.2.8 Generation of Wnt3a conditioned medium ................................................... 37 
5.2.9 Proliferation assay ......................................................................................... 37 
5.2.10 Apoptosis assay ............................................................................................. 37 




5.2.12 Invasion assay ................................................................................................ 38 
5.3 Protein chemistry and immunohistochemistry ...................................................... 39 
5.3.1 Protein isolation from cell culture ................................................................. 39 
5.3.2 Western blot ................................................................................................... 39 
5.3.3 Haematoxylin eosin (HE) staining ................................................................ 40 
5.3.4 Immunohistochemical staining of tissues ...................................................... 40 
5.3.5 Immunofluorescence staining ........................................................................ 40 
5.4 In vivo tumor model and animal experiments ....................................................... 41 
5.4.1 Chorio-allantoic membrane (CAM) assay ..................................................... 41 
5.4.2 Breeding of mice ........................................................................................... 42 
5.4.3 Tissue biopsies and genotyping of mice ........................................................ 42 
5.4.4 Monitoring of RMS bearing mice ................................................................. 42 
5.4.5 Preparation and isolation of RMS ................................................................. 42 
5.5 Statistics ................................................................................................................. 43 
6 Results ................................................................................................................... 44 
6.1 LEF1 and β-catenin expression in primary human RMS ...................................... 44 
6.2 In vivo effect of Wnt3a on RMS development ...................................................... 46 
6.3 Generation of stable LEF1 KD RMS cell lines ..................................................... 48 
6.4 Analysis of canonical WNT signaling activity in human RMS cell lines ............. 50 
6.5 Analysis of β-catenin functionality and LEF1-dependent expression of TCF 
factors in RMS cell lines ....................................................................................... 56 
6.5.1 Effect of Wnt3a on subcellular localization of β-catenin in RMS cell lines . 56 
6.5.2 Effect of LEF1 KD on the expression of TCF factors in RMS cell lines ...... 58 
6.6 Effects of LEF1 KD on cellular processes in RMS cell lines ............................... 59 
6.6.1 Effect on proliferation ................................................................................... 59 
6.6.2 Effect on apoptosis ........................................................................................ 59 
6.6.3 Effect on migration and invasion................................................................... 59 




6.7 Effect of LEF1 KD on the expression of muscle differentiation markers in RMS 
cell lines ................................................................................................................. 63 
6.8 WNT5A expression in primary human RMS ........................................................ 66 
6.9 Effect of LEF1 KD on WNT5A expression in RMS cell lines .............................. 67 
6.10 Effect of LEF1 on WNT5A expression in RMS cell lines .................................... 68 
7 Discussion ............................................................................................................. 72 
7.1 Wnt3a-driven β-catenin dependent (canonical) WNT signaling seems to play a 
subordinate role in RMS ........................................................................................ 73 
7.2 LEF1 can reduce tumor progression and can induce myodifferentiation in a subset 
of RMS .................................................................................................................. 77 
7.3 Interaction of LEF1 and WNT5A in RMS-13 cells .............................................. 79 
7.4 Outlook .................................................................................................................. 81 
8 References............................................................................................................. 85 
9 Abbreviations ....................................................................................................... 95 
10 Acknowledgement ................................................................................................ 99 
 List of Figures 
IX 
 
List of Figures 
Figure 1: Overview of β-catenin dependent (canonical) WNT signaling. ............................ 5 
Figure 2: Overview of β-catenin independent (non-canonical) WNT signaling. .................. 8 
Figure 3: Immunohistochemical analyses of LEF1 and β-catenin in human RMS biopsies.45 
Figure 4: qRT-PCR analyses of LEF1, CTNNB1 and AXIN2 in human RMS biopsies. ..... 46 
Figure 5: Effect of Wnt3a on RMS development. ............................................................... 47 
Figure 6: Generation of stable LEF1 knockdown (LEF1 KD) RMS cell lines and 
expression analyses of WNT target genes. .......................................................................... 49 
Figure 7: Activation of β-catenin dependent WNT signaling in human RMS cell lines. ... 51 
Figure 8: β-catenin driven WNT signaling activity in RMS cell lines. ............................... 52 
Figure 9: Control experiments of data shown in Figure 8. .................................................. 53 
Figure 10: LEF1-dependent modulation of β-catenin driven WNT signaling activity in 
RMS cell lines. .................................................................................................................... 55 
Figure 11: Localization of β-catenin after Wnt3a stimulation in RMS cell lines. .............. 57 
Figure 12: LEF1-dependent expression of TCF factors in RMS cell lines. ........................ 58 
Figure 13: LEF1-dependent regulation of proliferation, apoptosis, migration and 
invasiveness of RMS cell lines. ........................................................................................... 60 
Figure 14: LEF1-dependent regulation of proliferation and invasion of RMS-13 cell line in 
the CAM assay. ................................................................................................................... 62 
Figure 15: β-catenin KD in human RMS cell lines. ............................................................ 64 
Figure 16: LEF1-dependent expression of muscle differentiation markers in RMS cell 
lines. ..................................................................................................................................... 65 
Figure 17: Immunohistochemical and qRT-PCR analyses of WNT5A in human RMS 
biopsies. ............................................................................................................................... 67 
Figure 18: LEF1-dependent modulation of WNT5A expression in RMS cell lines. ........... 68 
Figure 19: LEF1-dependent modulation of WNT5A protein level in ARMS cell lines. .... 69 
Figure 20: LEF1-dependent modulation of pAKT/AKT protein level in ARMS cell lines. 70 
Figure 21: Effect of PI3K/pAKT/mTOR inhibitors on LEF1 protein levels in RMS-13.... 71 
Figure 22: Current model of the interplay of LEF1, WNT5A, PI3K and c-MYC in ARMS.81 
 List of Tables 
X 
 
List of Tables 
Table 1: List of laboratory equipment ................................................................................. 12 
Table 2: List of consumable materials ................................................................................. 14 
Table 3: Utilized reagents and chemicals ............................................................................ 16 
Table 4: List of applied inhibitors ....................................................................................... 18 
Table 5: Kits and ready-to-use reaction systems ................................................................. 18 
Table 6: Buffers and solutions and their respective composition ........................................ 19 
Table 7: Media and reagents used for cell culture of eukaryotic cells ................................ 21 
Table 8: List of eukaryotic cell lines and culture conditions ............................................... 22 
Table 9: Oligonucleotides for genotyping of mice .............................................................. 24 
Table 10: Oligonucleotides for qRT-PCR ........................................................................... 24 
Table 11: Oligonucleotides for transfection ........................................................................ 25 
Table 12: Plasmids used for human RMS cell lines ............................................................ 25 
Table 13: Antibodies for Western blot ................................................................................ 26 
Table 14: Antibodies for immunohistochemistry/immunofluorescence ............................. 26 
Table 15: List of used software ........................................................................................... 27 
Table 16: List of uses databases .......................................................................................... 28 
Table 17: Reaction mixture for genotyping of mouse tail or ear gDNA ............................. 31 
Table 18: PCR conditions for genotyping of mice .............................................................. 31 
Table 19: Reaction mixture for qRT-PCR ........................................................................... 32 
Table 20: Reaction mixture for restriction hydrolysis ......................................................... 33 
Table 21: Cell culture conditions for in vitro assays ........................................................... 34 






Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children 
and shows characteristics of skeletal muscle differentiation. RMS occur in two main 
histological subtypes in children: alveolar RMS (ARMS) and embryonal RMS (ERMS), 
which are associated with distinct genetic and molecular alterations. Despite more 
intensive therapies during the last decades, patients with metastatic RMS have a very poor 
prognosis. Thus, it is of uttermost importance to increase the knowledge of the basic 
biology of RMS and to develop new treatment strategies in order to improve the outcome 
of the disease.  
WNT signaling plays an important role in muscle development and differentiation and also 
contributes to a variety of human diseases including cancer. However, only few data on the 
role of WNT signaling in RMS have been published and are restricted to β-catenin 
dependent (canonical) WNT signaling. These data mainly support a tumor suppressive role 
of canonical WNT signaling in RMS besides promoting myogenic differentiation. 
Our findings now demonstrate that the prominent transcription factor of canonical WNT 
signaling LEF1/LEF1 can be highly expressed in primary human ARMS and ERMS 
samples. However, the common absence of nuclear β-catenin and downregulation of 
AXIN2 in these RMS samples indicate that canonical WNT signaling is not active and 
probably inhibited in RMS. Furthermore, our in vivo studies reveal that Wnt3a-driven 
canonical Wnt/β-catenin signaling does not play a prominent role in RMS pathogenesis in 
mice.  
To study the role of LEF1 in RMS in more depth, a stable LEF1 knockdown (LEF1 KD) in 
the two human ARMS cell lines Rh41 and RMS-13 and in the human ERMS cell line 
TE671 was established. Our data demonstrate that dependent on the cellular context, LEF1 
reduces the aggressiveness of RMS cells. Thus, LEF1 can induce pro-apoptotic signals and 
can suppress proliferation, migration and invasiveness – especially in the ARMS cell line 
RMS-13 – both in vitro and in vivo. This less aggressive phenotype is associated with 
reduced c-MYC and TCFs expression. Furthermore, LEF1 can induce myodifferentiation of 
RMS-13 cells. Importantly, this seems not to involve canonical β-catenin driven WNT 
signaling activity. Indeed, despite an upregulation of AXIN2, Wnt3a stimulation does 




ARMS cell lines. Together these data indicate that LEF1 has a tumor suppressive function 
and can induce myodifferentiation in a subset of RMS. This may also involve TCF factors 
whereas β-catenin activity plays a subordinate role.  
Interestingly, WNT5A a major player of β-catenin independent (non-canonical) WNT 
signaling is also overexpressed on protein and on transcript level in primary human ARMS 
and ERMS samples. Moreover, LEF1 mRNA levels tend to be positively correlated with 
that of WNT5A in primary human ARMS samples. This is similar to the ARMS cell line 
RMS-13, in which LEF1/LEF1 expression correlates with that of WNT5A/WNT5A. These 
data indicate that besides LEF1 also WNT5A might be involved in the pathogenesis and 
aggressiveness of ARMS. Furthermore, in RMS-13 cells, WNT5A expression is 
accompanied by activation of PI3K/AKT signaling and LEF1 expression is positively 
regulated by PI3K. We here propose a new model, in which LEF1 and WNT5A establish a 
positive feedback loop that involves activation of PI3K signaling and counteracts the 
aggressiveness of a subset of ARMS, which correlates with downregulation of c-MYC. 
Recently, activation of β-catenin driven WNT signaling has been proposed as a new 
treatment option for RMS. However, this may be only of benefit for specific subtypes of 
RMS, but not for those, in which tumor progression and myogenic differentiation is 
regulated via LEF1/WNT5A interactions in a non-canonical manner. Together, these data 
show that further investigations are needed to identify the specific RMS subtypes that may 
respond to activation of either canonical or LEF1/WNT5A-mediated non-canonical 







2.1 Rhabdomyosarcoma (RMS) 
Rhabdomyosarcoma (RMS) accounts for approximately 40 % of all soft tissue sarcoma in 
children and adolescents under the age of 20 years and therefore is the most common soft 
tissue sarcoma in children (Dagher et al., 1999; Ognjanovic et al., 2009). Primary RMS in 
children mainly occur in the head and neck region, the genitourinary tract, and the trunk or 
limb (reviewed in Sebire et al., 2003). These pediatric tumors are linked to the skeletal 
muscle lineage, because essentially all of them show nuclear expression of myogenic 
markers such as MYOGENIN and MYOD1 (Sebire et al., 2003). Based on 
histopathological features and distinct genetic alterations, RMS can be divided into two 
major subtypes in children that are alveolar RMS (ARMS) and embryonal RMS (ERMS). 
ERMS account for approximately two thirds of all RMS cases and frequently show loss of 
heterozygosity (LOH) at chromosome 11p15 (Dagher et al., 1999; Merlino et al., 1999; 
Ognjanovic et al., 2009). This subtype is histologically characterized by spindle-shaped 
cells with a stroma-rich appearance. ARMS exhibit small, round, densely appearing cells 
lined up along spaces reminiscent of pulmonary alveoli. This subtype can be further 
divided in fusion gene negative with 25 % and fusion gene positive ARMS with 75 % 
prevalence. The latter subgroup is characterized by t(2;13) or t(1;13) chromosomal 
translocations that lead to fusion genes encoding either PAX3-FOXO1 or PAX7-FOXO1 
fusion proteins (Dagher et al., 1999). ERMS are always fusion gene negative and are 
associated with a more favorable prognosis with a 5-year overall survival of approximately 
73 % compared to 48 % for ARMS (Dagher et al., 1999; Merlino et al., 1999; Ognjanovic 
et al., 2009). However, the survival rate for metastatic disease is only 10-30 % for ARMS 









2.2 WNT signaling 
The WNT pathway is a highly conserved signaling cascade, which controls many 
developmental processes, tissue regeneration and homeostasis, and also contributes to a 
variety of human diseases including cancer (reviewed in Clevers et al., 2012). The WNT 
ligands comprise a large family of secreted glycolipoproteins that can signal through 
different types of receptors activating a number of intracellular signaling pathways. WNT 
signaling can be generally divided into the canonical WNT pathway that involves 
β-catenin-mediated transcriptional activation, and the non-canonical WNT pathways that 
are β-catenin independent but share several components with the canonical cascade. 
2.2.1 β-catenin dependent (canonical) WNT signaling 
In the absence of WNT, the β-catenin dependent WNT signaling pathway is inactive 
(Figure 1A). In the inactive state, β-catenin is phosphorylated by the serine/threonine 
kinases glycogen synthase kinase 3 (GSK3) and casein kinase 1 (CK1) as a part of the 
destruction complex. This multiprotein complex furthermore comprises Dishevelled (Dvl), 
Axin, adenomatosis polyposis coli (APC) gene product and β-transducin repeat containing 
protein (β-Trcp). Phosphorylated β-catenin is subsequently ubiquitinated by the 
E3 ubiquitin ligase subunit β-Trcp, and degraded by the proteasome (reviewed in 
MacDonald et al., 2009). 
In the presence of WNT, the pathway is active (Figure 1B). WNT binds to the extracellular 
region of Frizzled (FZD) and its co-receptor low-density lipoprotein receptor-related 
protein 6 (LRP6) or LRP5. The formation of a WNT/FZD/LRP complex results in LRP6 
phosphorylation and the recruitment of Dvl, and the rest of the destruction complex to the 
receptors. This inhibits the destruction complex, which is followed by stabilization, 
accumulation and nuclear translocation of β-catenin where it binds to LEF1/T cell factor 
(TCF) transcription factors in a complex with other co-activators. This results in the 
activation of expression of WNT target genes including Cyclin D1, c-Myc and Axin2 
(for review see MacDonald et al., 2009; Belyea et al., 2012). Many of 
WNT/LEF1/TCF/β-catenin target genes are regulated context-dependently and are 
expressed in a tissue-specific or temporally restricted manner, which may explain how they 
achieve a wide diversity of transcriptional outputs in different cells, but also the 
heterogeneous responses of tumor cell lines to WNT ligands (Archbold et al., 2012; 






Figure 1: Overview of β-catenin dependent (canonical) WNT signaling. Schematic representation of the 
canonical WNT pathway in (A) off and (B) on state. (A) In the absence of the WNT ligand, the destruction 
complex composed of APC, Axin, CK1 and GSK3 presents β-catenin for phosphorylation by CK1 and 
GSK3. Phosphorylated β-catenin is ubiquitinated and degraded by the proteasome. (B) Upon WNT ligand 
binding, a WNT/FZD/LRP complex forms at the cell membrane, where the kinase activity of CK1 and GSK3 
is redirected toward LRP5/6 in complex with Axin and Dvl. Newly synthesized β-catenin is no longer 
phosphorylated, accumulates and translocates into the nucleus, and induces target gene expression along with 











































2.2.2 Lymphoid enhancer factor 1 (LEF1) 
Lymphoid enhancer factor 1 (LEF1) is a central member of the LEF/TCF family of 
transcription factors that mediate WNT signaling by recruiting the co-activator β-catenin to 
activate WNT target genes. In mammals, 4 LEF/TCF members exist, which are TCF7 
(TCF1), TCF7L1 (TCF3), TCF7L2 (TCF4), and LEF1 (TCF7L3) (reviewed in Arce et al., 
2006; Archbold et al., 2012). As the other TCFs, LEF1 contains a β-catenin-binding 
domain at the N-terminus, a high-mobility group (HMG) domain and a nuclear localization 
signal (NLS). The NLS is recognized directly by importin alpha subunits for nuclear 
import and the HMG domain recognizes the CCTTTGWW (W represents either T or A) 
DNA sequence, known as WNT responsive element (WRE). LEF1 also has a context-
dependent regulatory domain (CRD). According to the current knowledge, the CRD 
participates in repression of WNT responsive genes by recruiting pleiotropic co-repressors 
of the Groucho/Transducin-like enhancer of split (TLE) family (Figure 1A) (Arce et al., 
2006). Indeed, in the absence of the WNT signal many targets are strongly repressed by 
LEF1/TLE complexes (reviewed in Turki-Judeh et al., 2012; Agarwal et al., 2015). Upon 
WNT-induced β-catenin stabilization and nuclear accumulation, LEF1 interacts with 
β-catenin. This displaces Groucho/TLE from LEF1 and recruits other co-activators 
resulting in activation of target genes (Figure 1B). A plethora of co-activators have been 
identified and include BCL9 and Pygopus (Pygo), Mediator (for transcription initiation), 
p300/CREB-binding protein (CBP) and TRRAP/TIP60 histone acetyltransferases (HATs), 
MLL1/2 histone methyltransferases (HMTs), the SWI/SNF family of ATPases for 
chromatin remodeling, and the PAF1 complex for transcription elongation and histone 
modifications (MacDonald et al., 2009; Archbold et al., 2012). 
However, LEF1 also possesses transcriptional activity that is independent of β-catenin. 
Grumolato and colleagues uncovered a novel mechanism of LEF1 (and also TCF1) 
dependent transcription that bypasses β-catenin and increases expression of WNT target 
genes through interaction of LEF1 with members of the activating transcription factor 2 
(ATF2) family of transcriptions factors. Moreover, they revealed that ATF2-induced 
activation of LEF1 and TCF1 promotes cell growth of hematopoietic tumor cells in the 
absence of β-catenin stabilization (Grumolato et al., 2013). In addition, the intracellular 
domain of NOTCH1 (NICD) can function as a co-activator of LEF1 leading to the 
upregulation of target genes independently of β-catenin (Ross et al., 2001). Moreover, 




regulation of gene targets (reviewed in Arce et al., 2006). Finally, LEF1 together with 
TCF1 has intrinsic HDAC activity that can repress genes counteracting cellular 
differentiation in specific contexts (Xing et al., 2016).  
Because of these context dependent effects, LEF1 can function either as an oncogene or as 
a tumor suppressor. For example, transplantation of LEF1-transduced bone marrow leads 
to acute myeloid leukemia and B-precursor acute lymphoblastic leukemia (ALL) in the 
mouse (Petropoulos et al., 2008). Conversely, LEF1 can repress the transcription of MYC 
and thus acts as a tumor suppressor in a subset of human T-ALL cases (Gutierrez et al., 
2010). 
2.2.3 β-catenin independent (non-canonical) WNT signaling 
Some WNT ligands also activate the non-canonical WNT signaling pathways that are 
independent of β-catenin and known as the planar cell polarity (PCP) and the calcium-
dependent WNT (WNT/Ca
2+
) signaling pathways (Figure 2).  
The WNT/PCP pathway regulates acquisition of asymmetric cellular morphology, 
directional cell migration, oriented cell division and cellular orientation in complex tissues 
(Vladar et al., 2009; Kaucká et al., 2015). This pathway is activated via binding of WNT to 
FZD receptor and its co-receptors such as the tyrosine kinase-like orphan receptor (ROR) 1 
and 2, the receptor tyrosine kinase-like (Ryk) or the protein tyrosine kinase 7 (Ptk7) 
(Figure 2A) (Thiele et al., 2016). The FZD receptor recruits cytoplasmatic Dvl. This 
results in the activation of the small GTPases Ras homologue (Rho) and Ras-related C3 
botulinum toxin substrate (Rac) in parallel pathways. For activation of the Rho branch of 
signaling, Dvl forms a complex with both Dvl-associated activator of morphogenesis 1 
(DAAM1) and Rho, which causes activation of the effector Rho-associated kinase 
(ROCK). In the second branch of signaling, Dvl forms a complex with Rac, which in turn 
stimulates MAPK8 (JNK) activity (reviewed in Komiya et al., 2008).  
The WNT/Ca
2+
 pathway regulates calcium release from the endoplasmatic reticulum (ER) 
in order to control intracellular calcium levels (Figure 2B) and functions as a critical 
modulator of both the canonical and PCP signaling pathways (Komiya et al., 2008). The 
WNT/Ca
2+
 pathway is activated upon binding of WNT ligands to the FZD receptor leading 
to the activation of phospholipase C (PLC). If PLC is activated, the plasma membrane 




inositol 1,4,5-trisphosphate (IP3). IP3 triggers Ca
2+
 influx from the ER, which activates 
several Ca
2+
 sensitive effector proteins including protein kinase C (PKC), calcineurin and 
calcium/calmodulin-dependent kinase II (CaMKII; Komiya et al., 2008). These kinases 
regulate and activate a multitude of target proteins and can also block β-catenin dependent 
WNT signaling at several levels (Ishitani et al., 2003; Sato et al., 2010). 
 
 
Figure 2: Overview of β-catenin independent (non-canonical) WNT signaling. Schematic representation 
of the non-canonical (A) WNT/PCP and (B) WNT/Ca
2+
 pathways. (A) WNT/PCP signaling is transduced 
through FZD and its co-receptors such as ROR1/2, Ryk or Ptk7 leading to the activation of Dvl. Dvl through 
DAAM1 mediates activation of Rho, which in turn activates ROCK. Dvl also stimulates Rac activity, which 
leads to the activation of JNK. (B) WNT/Ca
2+
 signaling via FZD operates through Dvl-dependent activation 
of PLC, which leads to release of intracellular Ca
2+
. Elevated cytoplasmatic Ca
2+ 
levels induce activation of 
PKC, calcineurin (Cn) and CaMKII. 
  


































2.2.4 WNT5A signaling 
One prominent non-canonical WNT ligand is WNT5A that can activate both the 
WNT/PCP and the WNT/Ca
2+
 pathways (Hogan et al., 2003; Oishi et al., 2003; De, 2011). 
In the presence of the receptor FZD2, 3, 4, 5 and 6 and their co-receptors ROR1/2, 
WNT5A activates the WNT/Ca
2+
 signaling pathway (reviewed in De, 2011). This leads to 
the production of IP3, the release of Ca
2+
 from the ER and activation of CaMKII 
(see Chapter 2.2.3). WNT5A/ROR can also stimulate the WNT/PCP pathway by activation 
of c-Jun and JNK. Oishi and colleagues showed that, beside a physical interaction between 
WNT5A and ROR molecules, co-expression of WNT5A and ROR2 had an additive effect 
on phosphorylation of c-Jun and thus on JNK activity (Oishi et al., 2003). Furthermore, 
dependent on the cellular context and receptor availability, WNT5A can block or activate 
β-catenin dependent WNT signaling (Mikels et al., 2006; reviewed in Ford et al., 2013).  
WNT5A signaling is critical for regulating normal developmental processes, including 
proliferation, differentiation, migration, adhesion and polarity. However, the aberrant 
activation or inhibition of WNT5A signaling is emerging as an important event in cancer 
progression, exerting both oncogenic and tumor suppressive effects (reviewed in Asem et 
al., 2016). For example, low or loss of WNT5A expression is linked to an increased 
metastatic and invasive phenotype and poor prognosis in breast and colorectal cancers 
(reviewed in Kumawat et al., 2016). Likewise, strong expression of WNT5A correlates 
with cell motility and tumor invasiveness in several tumor entities e.g. of prostate cancer 
(Yamamoto et al., 2010) and melanoma (Weeraratna et al., 2002). On the other hand, 
deletion or loss of WNT5A expression is observed in mouse and human B cell lymphomas 
and myeloid leukemias revealing a tumor suppressive role (Liang et al., 2003; Yuan et al., 
2011). Furthermore, WNT5A has been shown to inhibit cell growth, migration and 
invasiveness of colorectal cancer and to have tumor suppressor activity in thyroid cancer 
by suppression of c-MYC (Kremenevskaja et al., 2005; reviewed in Kumawat et al., 2016).   
2.2.5 WNT signaling in RMS 
Currently, the knowledge about the role of WNT in RMS is sparse and restricted to 
β-catenin dependent WNT signaling. This is due to the fact that RMS do not show 
mutations in important components of the WNT signaling pathway such as β-catenin 




β-catenin is expressed cytoplasmatically in RMS and does not localize to the nucleus 
(Bouron-Dal Soglio et al., 2009; reviewed in Belyea et al., 2012). However, a recent paper 
now shows mutations in β-catenin in 3.3 % of ERMS (Shukla et al., 2012).  
In addition, Singh and colleagues showed that the Wnt/β-catenin signaling pathway is 
inhibited in an ERMS cell line derived from ERMS tumors formed in p53/c-fos double-
mutant mouse (Singh, S. et al., 2010). This cell line overexpressed Wnt2, Wnt10a and 
Wnt8b compared to normal myoblasts. However, the majority of downstream target genes 
of canonical Wnt/β-catenin signaling, such as c-Myc and cyclins, were not differentially 
expressed and the Wnt receptors Fzd1, 3 and 5, the signaling mediator Dvl, Lef1 and Pygo 
were downregulated. In addition, the most highly overexpressed genes were Wnt pathway 
inhibitors such as Sfrp2, Sfrp4, Dkk1 and Ndk1. TOPflash reporter assay confirmed that 
canonical Wnt/β-catenin signaling was downregulated in this ERMS cell line when 
compared with normal myoblasts. Furthermore, activation of the Wnt pathway by LiCl 
induced MyoD and MyHC expression levels and promoted myoblast fusion. In summary, 
these results suggest that activation of the Wnt pathway in RMS may mainly promote anti-
oncogenic effects and myogenic differentiation (Singh, S. et al., 2010; for review see 
Roma et al., 2012). With the exception of two ERMS samples, Annavarapu and colleagues 
confirmed the consistent and cytoplasmatic expression of β-catenin in primary human 
RMS (Annavarapu et al., 2013). In addition, they showed that the ARMS cell lines Rh4 
and Rh30 and the ERMS cell lines RD and RD18 express central regulatory 
WNT/β-catenin pathway proteins such as GSK3β, DVL3, AXIN1 and LRP6, and that this 
pathway is functionally active in response to recombinant Wnt3a by means of TOPflash 
reporter assay and AXIN2 Western blot analysis. Moreover, stimulation with recombinant 
Wnt3a let to nuclear translocation of β-catenin, which resulted in i) induction of the 
myogenic differentiation markers MYOGENIN, MYOD and MYF5 in both ARMS and 
ERMS cell lines and ii) a significant decrease in the proliferation rate of ARMS but not of 
ERMS. Due to these data, the authors conclude that β-catenin dependent WNT signaling in 
RMS promotes myogenic differentiation and probably plays a tumor suppressive role in 





3 Aim of the Study 
Canonical WNT/β-catenin signaling is required for normal muscle development and 
differentiation, and also contributes to a variety of human diseases including cancer. 
LEF1 – a central regulatory component of WNT signaling – is expressed in 50 % of 
primary human RMS, which is a tumor that originates from cells that normally develop 
into skeletal muscles. In this thesis, the role of LEF1 and WNT signaling was studied in 
more depth in this tumor entity.  
First, the role of canonical Wnt signaling activity on RMS growth was studied in a genetic 




) that develop RMS at a 
high incidence were crossed to mice expressing a hypomorphic Wnt3a allele. Second, we 
investigated whether the canonical WNT signaling pathway is generally active or can be 
activated in the human ARMS cell lines Rh41 and RMS-13 and in the ERMS cell line 
TE671, and if LEF1 is important in this process. For this purpose, stable LEF1 KD cells 
were used and TOP/FOP reporter assays and immunofluorescence staining were 
performed. Furthermore, we clarified a potential impact of LEF1 on the regulation of TCF 
factors in RMS. In addition, the stable LEF1 KD cells were analyzed with respect to 
proliferation, apoptosis, their migratory and invasive properties, and the expression of the 
muscle differentiation markers MYOD, MYH1, DESMIN and CKM. Finally, the influence 
of LEF1 on RMS growth, aggressiveness and progression was studied in vivo using the 
chick chorio-allantoic membrane (CAM) model.  
Since primary human RMS can also express the major player of non-canonical WNT 
signaling WNT5A and since LEF1 gene expression tends to be positively correlated with 
that of WNT5A in some primary human ARMS and in RMS-13 cells, RMS-13 control and 
RMS-13 LEF1 KD cells were further used to analyze the potential regulation and/or 





4.1 Technical equipment 
Table 1: List of laboratory equipment 
Equipment Supplier 
-20 °C Freezer  Liebherr GmbH, Ochshausen  
-80 °C Freezer (MDF-U71V)  Sanyo Electric Co., Ltd., Japan  
4 °C Fridge  Robert Bosch GmbH, Stuttgart  
Agarose gel electrophoresis chamber  Peqlab Biotechnology GmbH, Erlangen  
Autoclave (Systec DX-150)  Systec GmbH & Co. KG, Linden  
Biophotometer (6131)  Eppendorf AG, Hamburg  
Bunsen burner (Gasprofi 2scs)  WLD-TEC GmbH, Göttingen  
Centrifuges (Biofuge fresco, primo)  Kendro Laboratory Products GmbH, 
Hanau  
Cold Plate (EG 1150 C)  Leica Microsystems GmbH, Wetzlar  
Digital monochrome printer (P91D)  Mitsubishi, Ratingen  
Digital photo camera (PowerShot G2)  Canon Deutschland GmbH, Krefeld  
Dissecting set  Karl Hammacher GmbH, Solingen  
Electronic pipettor (Accu-jet)  Brand GmbH & Co. KG, Wertheim  
Electrophoresis System (XCell4 
SureLock
TM
 Midi-Cell)  
Invitrogen GmbH, Karlsruhe  
FACS Calibur  BD Biosciences GmbH, Heidelberg  
Freezing Container (Mr. Frosty
TM
)  Thermo Fisher Scientific GmbH, Schwerte  
Heating block (Thermomixer)  Eppendorf AG, Hamburg  
Heating stirrer (MR 3000/3001)  Heidolph Instruments GmbH & Co. KG, 
Schwabach  
High-precision scales (Sartorius Basic 
plus)  
Sartorius AG, Göttingen  
Hybridization oven (HB-1000 Hybridizer)  UVP, Inc., Upland, USA  






Incubator (6000, BBD 6220)  Kendro Laboratory Products GmbH, 
Hanau  
Inverted tissue culture fluorescence 
microscope (Axiovert 25)  
Carl Zeiss Jena GmbH, Jena  
Laboratory animal computed tomography 
system (QuantumFX)  
PerkinElmer Health Sciences, Hopkinton 
USA  
Liquid nitrogen tank  L’air liquid S.A., Paris, France  
Mastercycler (EP gradient S)  Eppendorf AG, Hamburg  
Microplate reader (Synergy Mx)  BioTek Instruments, Inc., Bad 
Friedrichshall  
Microscope (Olympus BX 60)  Olympus Deutschland GmbH, Hamburg  
Microtom (HN 40)  Leica Microsystems GmbH, Wetzlar  
Microwave (Dimension 4)  Panasonic, Hamburg  
Mini centrifuge  Carl Roth GmbH & Co. KG, Karlsruhe  
Multifuge (Heraeus 3LR)  Thermo Scientific, Wilmington, USA  
NEON Transfection System Thermo Scientific, Wilmington, USA  
Orbital shaker (Unimax 1010)  Heidolph Instruments GmbH & Co. KG, 
Schwabach  
Paraffin dispenser (Dispenser PAG 12)  Medite GmbH, Burgdorf  
Paraffin tissue floating bath  Medax GmbH & Co. KG, Rendburg  
PCR machine  Eppendorf, Hamburg  
pH-meter (inoLab pH Level 1)  WTW GmbH, Vienna, Austria  
Pipettes (Multipette, One-channel)  Eppendorf AG, Hamburg  
Power supply for electrophoresis  Peqlab Biotechnology GmbH, Erlangen  
Real-Time PCR System (ABI Prism 
7900HT)  
Life Technologies GmbH, Darmstadt  
Spectrophotometer (NanoDrop 8000)  Thermo Scientific, Wilmington, USA  







Tissue embedding and rehydrating 
machine (TP 1020)  
Leica Microsystems GmbH, Wetzlar  




Thermo Scientific, Wilmington, USA 
UV transilluminator  Intas Science Imaging GmbH, Göttingen  
Vacuum pump  Schütt Labortechnik, Göttingen  
Vortexer-Genie 2  Scientific Industries, Woburn, USA  




Sartorius, Göttingen  
 
4.2 Consumables 
Table 2: List of consumable materials 
Consumer good Supplier 
1.5 ml reaction tubes  Ochs GmbH, Bovenden/Lenglern  
1.5 ml safeseal microtubes  Sarstedt AG & Co., Nürnberg  
2.0 ml reaction tubes  Sarstedt AG & Co., Nürnberg  
15 ml centrifuge tubes  Greiner Bio-One GmbH, Frickenhausen  
50 ml centrifuge tubes  Greiner Bio-One GmbH, Frickenhausen  
96-well assay plate  Nunc GmbH & Co. KG, Wiesbaden  
96-well reaction plate (black)  Costar Corning Incorporated, Corning, 
USA  
96-well PCR plate (non-skirted)  4titude Ltd., Berlin  
384-well PCR plate (Framestar)  4titude Ltd., Berlin  




 II (2, 10, 20 ml)  BD Biosciences GmbH, Heidelberg  
BD Microfine + Demi  BD Biosciences GmbH, Heidelberg  
BD Plastipak  BD Biosciences GmbH, Heidelberg  





Consumer good Supplier 
Cell culture dishes (Nunclon Surface)  Nunc GmbH & Co.KG, Wiesbaden  
Cell culture inserts (24-well, 8 µm) BD Biosciences GmbH, Heidelberg  
Cell scraper  Sarstedt AG & Co., Nürnberg  
Combitips (0.2, 0.5, 2.5, 5, 10, 25, 50 ml)  Eppendorf AG, Hamburg  
Coverslips  Menzel GmbH & Co.KG, Braunschweig  
CryoPure tubes  Sarstedt AG & Co., Nürnberg  
Cuvette (UVette) Carl Roth GmbH & Co. KG, Karlsruhe 
Disposable needles (Sterican Ø 0,45 x 12 
mm)  
B. Braun Medical AG, Emmenbrücke  
Feeding tubes (1.0 x 60 mm)  Unimed SA, Lausanne, Schweiz  
Filter tips (10 μl)  Sarstedt AG & Co., Nürnberg  
Filter tips (100 μl, 200 μl, 1000 μl)  Kisker Biotech GmbH & Co. KG, 
Steinfurt  
Flow cytometry tube  Sarstedt AG & Co., Nürnberg  
Fluted filters  Sartorius AG, Göttingen  
Glassware  Schott AG, Mainz  
Milliporefilter (Nuclepore Track-Etch 
Membran)  
Whatman GmbH, Dassel  
Microscope slides (SuperFrost Plus)  Menzel GmbH & Co.KG, Braunschweig  
Neubauer counting chamber  Brand GmbH & Co KG, Wertheim  
Nitrocellulose membrane (Hybond ECL)  GE Healthcare Europe GmbH, Freiburg  
NuPAGE Novex 4-12 % Bis-Tris Midi Gel  Invitrogen GmbH, Karlsruhe  
Pasteur pipettes  Brand GmbH & Co.KG, Wertheim  
Petri dishes  Ochs GmbH, Bovenden/Lenglern  
Pipette tips (10 μl, 200 μl)  Ochs GmbH, Bovenden/Lenglern  
Pipette tips (20 μl, 1000 μl)  Sarstedt AG & Co., Nürnberg  
QPCR adhesive clear seal  4titude Ltd., Berlin  




Consumer good Supplier 
Serological pipettes (2 ml, 5 ml, 10 ml, 
25 ml)  
Sarstedt AG & Co., Nürnberg  
Sterile filter  Omnilab-Krannich, Göttingen  
SOC Medium Invitrogen GmbH, Karlsruhe 
Syringe (30, 50 ml)  Terumo Medical Corp., Elkton, MD, 
USA  
Tissue culture plates (6-, 12-, 24-well)  Sarstedt AG & Co., Nürnberg  
 
4.3 Reagents and chemicals 
Chemicals which are not listed below were purchased from Sigma-Aldrich Chemie GmbH, 
Steinheim.  
Table 3: Utilized reagents and chemicals 
Reagents and chemicals Supplier 
50 bp, 100 bp plus, 1 kb DNA Ladder  Fermentas GmbH, St. Leon-Rot  
7-Amino-Actinomycin D (7-AAD) BD Biosciences GmbH, Heidelberg 
Agarose  Bio-Budget Technologies GmbH, Krefeld  
Ampuwa  Fresenius Kabi Deutschland GmbH, Bad 
Homburg  
APC AnnexinV BD Biosciences GmbH, Heidelberg  
Boric acid  Carl Roth GmbH & Co. KG, Karlsruhe  
Bovine serum albumin (BSA)  Carl Roth GmbH & Co. KG, Karlsruhe  
Chloroform  Carl Roth GmbH & Co. KG, Karlsruhe  
Citric acid  Carl Roth GmbH & Co. KG, Karlsruhe  
Deoxyribonucleotide triphosphate (dNTP)  Roche Diagnostics GmbH, Mannheim  
Dithiothreitol, 100 mM (DTT)  Invitrogen GmbH, Karlsruhe  
DNase/RNase-free distilled water  GIBCO Invitrogen GmbH, Karlsruhe  
Eosin Y  Merck KGaA, Darmstadt  




Reagents and chemicals Supplier 
Ethidium bromide (0.07 %)  inna-TRAIN-Diagnostics, Kronberg  
Ethylenediaminetetraacetic acid (EDTA)  ICN Biochemicals Inc., AuRORa, USA  
EtOH 99 % denatured  CVH Chemie-Vertrieb GmbH & Co. 
Hannover KG, Hannover  
Haematoxylin, Mayer’s  Merck KGaA, Darmstadt  
Isopropyl alcohol  Carl Roth GmbH & Co. KG, Karlsruhe  
Laemmli loading buffer, non-reducing, 4 x  bioPlus, Mol, Belgium  
Matrigel Costar Corning Incorporated, Corning, 
USA 
Methanol  Carl Roth GmbH & Co. KG, Karlsruhe  
NovocastraTM Epitope Retrieval Solution, 
pH 6.0; pH 9.0 
Leica Microsystems GmbH, Wetzlar 
NuPAGE MES SDS Running Buffer, 20 x  Invitrogen GmbH, Karlsruhe  
Paraformaldehyde  Carl Roth GmbH & Co. KG, Karlsruhe  
Peroxidase-Blocking solution DAKO GmbH, Hamburg  
Pertex mounting medium  Medite Medizintechnik GmbH, Burgdorf  
Phosphatase inhibitor cocktail tablets 
(PhosSTOP)  
Roche Diagnostics GmbH, Mannheim  
Phosphate buffered saline (PBS)-Tablets  GIBCO Invitrogen GmbH, Karlsruhe  
Potassium aluminum sulfate  Merck KGaA, Darmstadt  
Powdered milk  Carl Roth GmbH & Co. KG, Karlsruhe  
ProLong Gold antifade mountant with 
DAPI 
Thermo Fisher Scientific GmbH, Schwerte 
Propidium Iodide (PI)  Miltenyi Biotec, Bergisch Gladbach  
Protease inhibitor cocktail tablets 
(Complete, mini)  
Roche Diagnostics GmbH, Mannheim  
Proteinase K  Carl Roth GmbH & Co. KG, Karlsruhe  
Random Hexamer-Oligonucleotides  Invitrogen GmbH, Karlsruhe  
SeeBlue
®
 Plus2 Pre-Stained Standard  Invitrogen GmbH, Karlsruhe  




Reagents and chemicals Supplier 
Trichloro acetaldehyde hydrate  Merck KGaA, Darmstadt  
TRIzol Reagent  Invitrogen GmbH, Karlsruhe  
Xylene  J.T. Baker B.V., Deventer, Netherlands  
 
4.4 Signaling pathway inhibitors  
Drugs, their appropriate solvents and final concentrations for in vitro analyses are listed in 
Table 4. 
Table 4: List of applied inhibitors 
Inhibitor Solvent Concentration Supplier 
GDC-0941  DMSO  10 μM Genentech, San Francisco, USA  
MK-2206  DMSO  1 μM Selleckchem, Munich  
PI103  DMSO  3 μM Axxora Deutschland GmbH, 
Lörrach  
 
4.5 Kits and ready-to-use reaction systems 
Unless indicated otherwise, all kits and ready-to-use reaction systems were used according 
to the manufacturer’s instructions. 
Table 5: Kits and ready-to-use reaction systems 




Detection Reagents  
GE Healthcare Europe GmbH, Freiburg 
10 x AnnexinV binding buffer  BD Biosciences GmbH, Heidelberg  
Cell Proliferation ELISA, BrdU 
(chemiluminescent)  
Roche Diagnostics GmbH, Mannheim  
Dual-Luciferase
®
Reporter Assay System Promega GmbH, Mannheim 
NEON Transfection Kit Thermo Scientific, Wilmington, USA 
Pierce BCA Protein Assay Kit  Thermo Fisher Scientific GmbH, Schwerte  





Reaction system Supplier 
PureLink
®
HiPure Plasmid Filter 
Midiprep Kit 
Invitrogen GmbH, Karlsruhe 
PureLink
®
HiPure Plasmid Midiprep Kit Invitrogen GmbH, Karlsruhe 
Reverse Transcriptase (SuperScriptII
®
)  Invitrogen GmbH, Karlsruhe  
RevertAid
TM
 H Minus First Strand cDNA 
Synthesis 
Thermo Fisher Scientific GmbH, Schwerte 
Taq-Polymerase (MolTaq)  Molzym GmbH & Co. KG, Bremen  
 
4.6 Buffers and solutions 
Unless mentioned otherwise, all solutions were prepared with double distilled water 
(ddH2O). 
Table 6: Buffers and solutions and their respective composition 
Buffer  Composition 
6 x SDS loading buffer 35 % (v/v) Glycerol  
9 % (w/v) SDS  
8.5 % (w/v) DTT  
0.1 % (w/v) Bromphenolblue  
dissolved in Upper gel buffer 
10 x PBS, pH 7.4 1.4 M NaCl  
65 mM Na2HPO4  
27 mM KCl  
15 mM KH2PO4 
10 x Tris-boric acid-EDTA 
(TBE), pH 8.0 
890 mM Tris/HCl  
730 mM Boric acid  
12.5 mM EDTA 
10 x Tris-buffered saline 
(TBS), pH 7.4 
150 mM NaCl  
10 mM Tris/HCl, pH 8.0 
Blotting buffer  
 
200 mM Glycine  
25 mM Tris  




Buffer  Composition 
BSA-azide 0.02 % Sodium azide  
2 % BSA  
dissolved in TBST 
Cresol 0.1 % (w/v) Cresol  
saturated sucrose solution 
dNTP-Mix 10 mM dATP  
10 mM dCTP  
10 mM dGTP  
10 mM dTTP 
 
Eosin solution 80 % (v/v) EtOH 
1 % (w/v) Eosin y (water soluble) 
Haematoxylin solution, 
Mayer’s 
5 % (w/v) Potassium aluminum sulfate  
5 % (w/v) Trichloro acetaldehyde hydrate  
1 % (w/v) Citric acid  
0.1 % (w/v) Haematoxylin  
0.015 % (w/v) Sodium iodate 
LB-agar 1.5 % (w/v) Agar in LB-medium 
Lysis buffer, pH 8.8 120 mM NaCl  
30 mM Tris/HCl, pH 7.5  
10 % (v/v) Glycerol  
1 % (v/v) Triton X-100  
Protease and phosphatase inhibitors (1 tablet/50 ml) 
added directly before use:   
2 mM DTT  
500 μM Phenylmethanesulfonylfluoride (PMSF)  
Lysogeny broth medium  
(LB medium) 
1 % (w/v) Bacto-tryptone 
1% (w/v) NaCl (pH 7.0) 
0.5 % (w/v) Yeast extract 
Paraformaldehyde (PFA) 4 % (w/v) Paraformaldehyde dissolved in PBS 




Buffer  Composition 
Proteinase K, pH 8.0 50 mM Tris/HCl 
5 mM EDTA 
10 mg/ml Proteinase K 
STE-Buffer, pH 8.0 100 mM NaCl 
50 mM Tris/HCl 
1 mM EDTA 
1 % (w/v) SDS 
TBS-Triton X-100  0.1 % Triton X-100 dissolved in TBS 
TBS-Tween (TBST) 0.05 % Tween-20 dissolved in TBS 
Trypan blue 0.4 % (w/v) Trypan blue dissolved in PBS 
Upper gel buffer, pH 6.8 6 % (w/v) Tris 
0.4 % (v/v) SDS 
 
4.7 Media 
4.7.1 Media and agar plates for culture of prokaryotic cells 
LB medium and LB agar plates were prepared as described in Table 7. After autoclaving 
and cooling to 55 °C either 50 μg/ml ampicillin or 25 μg/ml kanamycin (Carl Roth GmbH, 
Karlsruhe) were added. Both, media and plates, were stored at 4 °C. 
4.7.2 Media and reagents for culture of eukaryotic cells 
Cell culture media and supplements for culture of eukaryotic cell lines are listed in Table 7. 
Table 7: Media and reagents used for cell culture of eukaryotic cells 
Media and reagents Supplier 
Accutase  PAA Laboratories GmbH, Pasching  
Dulbecco’s Modified Eagle Medium 
(DMEM)  
Gibco, Invitrogen GmbH, Karlsruhe  
Fetal calf serum (FCS)  Gibco, Invitrogen GmbH, Karlsruhe  
G 418 disulfate salt solution (50 mg/ml) Sigma-Aldrich Chemistry GmbH, 
Steinheim 
Penicillin (10.000 U/ml)/Streptomycin 
(10 mg/ml) (P/S)  




Media and reagents Supplier 
Puromycin dihydrochloride (10 mg/ml) Sigma-Aldrich Chemistry GmbH, 
Steinheim 
RPMI 1640 (RPMI)  Gibco, Invitrogen GmbH, Karlsruhe  
TrypLE Express  Gibco, Invitrogen GmbH, Karlsruhe  
Taq-Polymerase (MolTaq)  Molzym GmbH & Co. KG, Bremen  
 
4.8 Biological material 
4.8.1 Bacterial strains 
For transformation and amplification of plasmid DNA the chemical competent 
Escherichia coli (E. coli) strain DH5α (Invitrogen GmbH, Karlsruhe) was used. 
4.8.2 Eukaryotic cell lines 
The eukaryotic cell lines used in this thesis and their appropriate culture conditions are 
listed in Table 8.  
Table 8: List of eukaryotic cell lines and culture conditions 
RMS cell line Subtype Medium and supplements Supplier 
Rh41  human ARMS  RPMI, 20 % FCS, 1 % P/S  ATCC 
RMS-13  human ARMS  RPMI, 10 % FCS, 1 % P/S  ATCC  
TE671 human ERMS  RPMI, 10 % FCS, 1 % P/S  ATCC  
Other cell 
line 
Origin Medium and supplements Supplier 
HEK293 human embryonic 
kidney 
DMEM, 10 % FCS, 1 % P/S ATCC 
Lcells murine fibroblasts DMEM, 10 % FCS, 1 % P/S ATCC 
Wnt-3A Lcells  murine fibroblasts 
stably overexpressing 
Wnt3a 
DMEM, 10 % FCS, 1 % P/S, 





4.8.3 Mouse lines 








) mice, which were obtained from the 
Department of Developmental Genetics, Max-Planck-Institute for Molecular Genetics, 
Berlin. The vt (vestigial tail) mutation is a hypomorphic Wnt3a allele that in the 
homozygous state results in loss of caudal vertebrae and thus loss of the tail (Greco et al., 




 were on a 50 % Balb/c and a remaining undefined 





 littermates served as control group. The Wnt
vt/vt
 genotype was 
determined by lack of tail (Greco et al., 1996). Primers and respective PCR conditions for 
genotyping of Ptch
del/+ 
mice are shown in Table 9 and Table 18. 
The heterozygous Ptch
del/+ 
mice were generated and bred in-house. In Ptch
del/+ 
mice 
exons 8 and 9 of the Ptch gene are deleted resulting in an aberrant Ptch transcript (Zibat et 
al., 2009; Nitzki et al., 2012).  
All experiments using animals were performed in agreement with all relevant legal and 
ethical requirements.  
4.8.4 Biopsies 
A tissue microarray (TMA) with 125 RMS biopsies from the Paediatric Tumor Register, 
Kiel, Germany and 20 fresh-frozen RNA samples from the CWS (“Cooperative 
Weichteilsarkom Studiengruppe”) tissue bank, Stuttgart, Germany (S1 - S20) were studied. 
Histopathology of all cases was centrally reviewed by Prof. I. Leuschner (Paediatric Tumor 
Registry, Kiel, Germany). All patients were treated according to CWS protocols. All 
studies were approved by the appropriate ethics and review committees. Written informed 
consent according to the Declaration of Helsinki was obtained from all patients or their 
legal guardians, depending on the patients’ age. 
4.9 Synthetic DNA-oligonucleotides 
Synthetic DNA-oligonucleotides (primers) were obtained from Eurofins MWG Operon, 
Ebersberg. For long-term storage (at -80 °C) 100 μM stock solutions in ddH2O were 





PCR for genotyping of mice was performed using the primers presented in Table 9.  




Primer sequence  
(5’-3’ orientation) 
Reference 












del: deletion, wt: wildtype  
 
Oligonucleotides used for analysis of gene expression levels via quantitative real-time PCR 
(qRT-PCR) are listed in Table 10. All primer pairs were intron-flanking, except of the 
primers for 18S and hMYOD that were located within a single exon. 
Table 10: Oligonucleotides for qRT-PCR 
Transcript Primer name 
















































































































* oligonucleotides used for qRT-PCR analyses of primary human ARMS and ERMS samples 
 
4.10 Synthetic RNA-oligonucleotides 
The following RNA-oligonucleotides were used for knockdown experiments in human 
RMS cell lines.  
Table 11: Oligonucleotides for transfection 
Application RNA Information/ Sequence Supplier 
β-catenin 
knockdown 





shRNA  TGGAGTTGACATCTGATGG 
(mature sequence) 
Thermo Scientific  
scrambled 
siRNA  
siRNA  AllStars negative Qiagen  
 
4.11 Plasmids 
The following plasmids were used for transfection and viral transduction of human RMS 
cell lines.  
Table 12: Plasmids used for human RMS cell lines 
Plasmid name Application Supplier/ Reference 
pCl-neo-β-cateninS33Y Dual-Luciferase (Morin et al., 1997) 
pCR3.1 Dual-Luciferase Invitrogen GmbH, Karlsruhe 
pGIPZ Lentiviral transduction GIPZ Lentiviral shRNAmir 
Library, Thermo Scientific Open 
Biosystems 
pRL-CMV Dual-Luciferase Promega GmbH, Mannheim 
SuperTOPFlash Dual-Luciferase (Korinek et al., 1997) 






The following antibodies in Table 13 were used for Western blot of human RMS cell lines. 
Antibodies used for immunohistochemistry of primary RMS samples and for 
immunofluorescence staining of human RMS cell lines are shown in Table 14. 
Table 13: Antibodies for Western blot 
Antibody Dilution Source Supplier 
Primary antibody    
Anti-AKT; (610861)  1:1000  Mouse, mAB  BD Biosciences  
Anti-β-Actin; (13E5)  1:1000  Rabbit, mAB  Cell Signaling  
Anti-β-catenin; (610153) 1:10000 Mouse, pAB  Beckton Dickinson 
GmbH 
Anti-HSC-70; (sc-7298)  1:10000  Mouse, mAB  Santa Cruz  
Anti-LEF1; (C18A7) 1:1000 Rabbit, mAB Cell Signaling 
Anti-pAKT (Ser473); 
(193H12)  
1:1000  Rabbit, mAB  Cell Signaling  
Anti-WNT5A; (MAB645) 1:2000 Rat, mAB R&D Systems 
Secondary antibody    
Anti-Mouse/HRP; (NA931)  1:5000  Sheep, pAB  GE Healthcare  
Anti-Rabbit/HRP; (A0545)  1:5000  Goat, pAB  Sigma-Aldrich  
Anti-Rat/HRP; (3030-05) 1:10000 Goat, pAB Southern Biotech 
mAB: monoclonal antibody, pAB: polyclonal antibody 
 
Table 14: Antibodies for immunohistochemistry/immunofluorescence 
Antibody Dilution Source Supplier 
Primary antibody    
Anti-β-catenin; (610153) 1:250  Mouse, pAB  Beckton Dickinson 
GmbH 
Anti-β-catenin; (CAT-5H10)* 1:200  Mouse, mAB  Zymed 
Anti-WNT5A; (MA5-15511, 
clone 3D10)* 
1:100 Mouse, mAB ThermoFisher 
Anti-HLA-A,B,C; (311402) 1:100 Mouse, mAB BioLegend 




Antibody Dilution Source Supplier 
Secondary antibody    
Anti-Mouse Alexa Fluor 594 
IgG2a (γ2a); (A-21135) 
1:200 Goat, pAB ThermoFisher 
Anti-Mouse Rhodamine 
(TRITC) (H+L); (715-025-150) 
1:200 Donkey, pAB Jackson 
ImmunoResearch 






*antibodies used for immunohistochemistry; mAB: monoclonal antibody, pAB: polyclonal antibody 
 
4.13 Software 
Table 15: List of used software 
Software Developer 
Adobe Photoshop CS5  Adobe Systems Incorporated, San Jose, USA  
AlphaView Q SA 3.2.2  Cell Bioscience, California, USA  
CellSens Dimension  Olympus GmbH, Hamburg  
Endnote X5  Thomson ISI ResearchSoft, California, USA  
FlowJo  Tree Star Inc., Oregon, USA  
GraphPad Prism 6  GraphPad Software, Inc., La Jolla, CA, USA  
Intas GDS  Intas Science Imaging Instruments GmbH, 
Göttingen  
Gen5 1.11  BioTek Instruments, Inc., Bad Friedrichshall  
Microsoft Office  Microsoft Co., Redmont, USA  
SDS 2.2  Applied Biosystems, Darmstadt  










Ensembl  http://www.ensembl.org/index.html  
MGI 3.43-mouse genome informatics  http://www.informatics.jax.org/  
National Center for Biotechnology 







5.1 Molecular biology methods 
5.1.1 Nucleic acid isolation 
5.1.1.1 Isolation of genomic DNA 
For isolation of genomic DNA (gDNA) from mouse tissue, tail or ear biopsies were 
incubated overnight at 55 °C in 500 μl of STE buffer containing 0.5 mg/ml Proteinase K. 
Afterwards undigested tissue debris was removed by centrifugation for 10 min at 
13000 rpm. The supernatant was transferred into a fresh reaction tube containing 1 ml cold 
99 % EtOH and was shaken thoroughly to precipitate the nucleic acid. The gDNA was 
pelleted by centrifugation (25 min, 13000 rpm), washed with 500 μl 70 % ethanol and 
centrifuged again (10 min, 13000 rpm). Finally, the gDNA was dried for 10 min at 55 °C, 
solved in 125 μl ddH2O for 10 min at 42 °C and 1400 rpm and stored at -20 °C for further 
analyses. 
5.1.1.2 Isolation of total RNA 
Extraction of total RNA from cell culture and RMS biopsies was performed by using 
TRIzol reagent according to the manufacturer’s instructions. All steps were carried out on 
ice if not otherwise stated to avoid RNA degradation. Briefly, the cells were washed with 
cold PBS and detached by adding 1 ml TRIzol. Samples were transferred into 2 ml reaction 
tubes, vortexed for 2 min and incubated for 5 min at room temperature (RT). Subsequently, 
200 µl of chloroform were added followed by vortexing for 15 sec and incubation for 
another 3 min at RT. After phase separation by centrifugation (10 min, 13000 rpm, 4 °C) 
the upper aqueous phase (containing the RNA) was transferred into 1 ml isopropyl alcohol 
and precipitated overnight at -20 °C. Afterwards the samples were centrifuged (30 min, 
13000 rpm, 4 °C), the supernatant was removed and the pellet was washed two times with 
500 μl 70 % DNase/RNase-free EtOH (-20 °C) by centrifugation (10 min, 13000 rpm, 
4 °C). The pellet was dried for 10 min at RT and dissolved in DNase/RNase-free H2O for 
5-10 min at 56 °C. The RNA was stored at -80 °C before use. 
5.1.1.3 Medium-scale plasmid purification 





HiPure Plasmid Filter Midiprep kit according to the manufacturer’s 




plasmid purity, the plasmid DNA was precipitated by isopropyl alcohol. In brief, an equal 
volume of isopropyl alcohol was added to the plasmid DNA solution, mixed thoroughly 
and precipitated overnight at -20 °C. The DNA was pelleted by centrifugation (30 min, 
13000 rpm, 4 °C), washed with 500 μl 70 % DNase/RNase-free EtOH (-20 °C) by 
centrifugation (10 min, 13000 rpm, 4 °C) and dried at RT for 10 min. Finally, the plasmid 
DNA was resuspended in DNase/RNase-free H2O for 10 min at 42 °C and 1400 rpm and 
stored at -20 °C. 
5.1.2 Photometric quantification of nucleic acids 
DNA and RNA concentration was quantified using a spectrophotometer (NanoDrop 8000) 
by determination of the optical density at 260 nm (OD260). Since an OD260 of 1.0 
corresponds to 50 µg/ml pure DNA or 40 µg/ml pure RNA, concentrations were calculated 




)=OD260 x 50 (DNA) or 40 (RNA) 
Because the OD at 280 nm (OD280) provides the protein concentration of the sample, the 
ratio OD260/OD280 was used to determine nucleic acid purity. A ratio of 1.8 and 2.0 is 
generally considered for pure DNA and RNA preparation, respectively. 
5.1.3 Reverse transcription of RNA (cDNA synthesis) 
For synthesis of complementary DNA (cDNA) from cultured cells, 2 μg of RNA were 
reversely transcribed using the SuperScriptII Reverse Transcriptase System in a final 
reaction volume of 20 μl. The RNA was incubated with 250 ng hexamers for 10 min at 
70 °C. Afterwards 10 mM DTT and 0.5 mM dNTPs in 1st strand buffer were added and 
incubated at RT for 10 min. Following pre-warming of the samples to 42 °C for 2 min, 1 μl 
of SuperScriptII (200 U/μl) was added and the mixture was incubated for 1 h at 42 °C. The 
synthesis reaction was stopped at 70 °C for 10 min. Assuming that the reverse transcription 
reaction is 50 % efficient, the final concentration of cDNA was 50 ng/µl.  
Furthermore, cDNA of 20 fresh-frozen RNA samples from the CWS (“Cooperative 
Weichteilsarkom Studiengruppe”) tissue bank, Stuttgart, Germany was synthesized by 
Dr. Katja Simon-Keller using the RevertAid
 
H Minus First Strand cDNA Synthesis Kit and 





5.1.4 Polymerase chain reaction (PCR) 
5.1.4.1 PCR-based genotyping of mouse tail or ear gDNA 
PCR-based amplification of gDNA was carried out in reaction volumes of 10 or 20 μl per 
assay and performed with the reagents and final concentrations shown in Table 17.  
Table 17: Reaction mixture for genotyping of mouse tail or ear gDNA 
Concentration Component 
10-100 ng   gDNA template 
0.5 µM  forward primer  
0.5 µM  reverse primer  
0.2 mM  dNTP-Mix  
10 % (v/v)  Cresol  
1x  Polymerase buffer  
0.1 U  Taq-Polymerase  
 
The primer sequences used for genotyping are given in Table 9 and respective PCR 
conditions are shown in Table 18.  
Table 18: PCR conditions for genotyping of mice 
                   Step Ptch del Ptch wt 
1 Initiation 5 min 2 min 
2 Denaturation 1 min 20 sec 
3 Annealing 1 min 20 sec 
4 Elongation 3 min 45 sec 
del: deletion, wt: wildtype 
  
The steps 2 to 4 were repeated for 35 cycles. The reaction was terminated by a final 





5.1.4.2 Quantitative Real-Time PCR (qRT-PCR) 
Gene expression was analyzed using SYBR Green based assays. Primers for amplification 
of the target transcripts are listed in Table 10. The assays were performed in a total 
reaction mixture of 10 μl using the reagents listed in Table 19. Amount of ddH20 and 
SYBR Green depended on the analyzed gene. 
Table 19: Reaction mixture for qRT-PCR 
Amount/ Concentration Component 
2 µl   cDNA template 
0.4 µM  forward primer  
0.4 µM  reverse primer  
2.2 or 3.2 µl ddH20  
4 or 5 µl SYBR Green  
 
Gene expression levels were calculated using the standard curve method. For 
quantification of the RNA levels a standard curve for each respective gene was prepared by 
5-fold serial dilutions of 20 ng cDNA (80 pg cDNA for 18S rRNA) of a standard sample. 
Standard samples were derived from tissue or cells known to express the target gene. The 
logarithm of each known cDNA concentration in the dilution series was plotted against the 
respective measured cycle threshold. The derived linear trend line with the corresponding 
equation (y = mx + b) served to interpolate the amount of cDNA in each sample. Finally, 
the transcript levels of each sample were normalized to the expressed housekeeper gene 
18S rRNA. The samples were measured in triplicates. Analysis was done using the 
SDS 2.2, Microsoft Excel and GraphPad Prism 6 software. 
Gene expression analyses of primary human ARMS and ERMS from fresh-frozen RNA 
samples were performed by Dr. Katja Simon-Keller on the Step one plus system. 
Amplification of GAPDH mRNA served to normalize the amount of sample DNA. The 




5.1.5 Agarose gel electrophoresis 
Gel electrophoresis was performed to separate DNA fragments by their size. Agarose gels 
were prepared by boiling 1 % to 2 % (w/v) agarose in 1 x TBE buffer for 2-3 min at 
1000 W in a microwave. After cooling down, liquid gels were supplemented with 
5-10 drops of 0.07 % ethidium bromide and polymerized at RT. Afterwards gels were 
placed in 1 x TBE buffer in an electrophoresis chamber, and an appropriate DNA ladder 
and the DNA samples were loaded onto the gels. The gels were run constantly at 100 to 
150 V. For documentation an UV transilluminator was used.  
5.1.6 Cloning techniques 
5.1.6.1 Transformation of bacteria 
50 µl competent E. coli DH5α were thawed on ice, mixed with 50-100 ng of plasmid DNA 
and incubated on ice for 20 min. Following a 45 sec heat shock at 42 °C, the samples were 
returned to ice for 2 min before adding 500 µl of SOC medium (super optimal broth with 
catabolite repression medium). The bacterial solution was gently shaken at 900 rpm and 
37 °C for 1 h. 25-100 µl of the solution was plated out onto LB agar plates containing the 
adequate antibiotics and incubated ON at 37 °C. The next day, Midi DNA preparations 
(see Chapter 5.1.1.3) were started by picking single bacterial colonies that were inoculated 
into 100 ml LB medium containing the adequate antibiotic and incubated at 37 °C and 
225 rpm ON. 
5.1.6.2 Restriction hydrolysis 
For test restriction of plasmids for TOP/FOP reporter assays (see Table 12, see 
Chapter 5.2.6) the total reaction mixture of 10 µl was prepared as shown in Table 20 with 
the appropriate enzymes and buffers according to the manufacturer’s instructions. 
Table 20: Reaction mixture for restriction hydrolysis 
Amount/ Concentration Component 
100-200 ng    plasmid DNA 
0.1 U  restriction enzyme  
1 x  restriction buffer 





If necessary and possible a double restriction digest was performed and each reaction was 
carried out for 1 h at the optimal temperature for each enzyme. Restriction hydrolysis was 
stopped by heat-inactivation if required. Finally, the sample DNA was separated by 
agarose gel electrophoresis. All used enzymes were purchased from NEB (Ipswich, USA) 
or Invitrogen (Karlsruhe). 
5.2 Cell biology methods 
5.2.1 Culture of eukaryotic cells 
All eukaryotic cell lines were cultured in an incubator at constant 37 °C, 5 % CO2 and 
95 % humidity. Every second to forth day the media were refreshed and cells were split 
when reaching 80 % to 90 % confluence. Splitting of the cells was performed by detaching 
the cells with 1-3 ml of TrypLE Express. After the cells started to detach the reaction was 
stopped by adding FCS-containing medium. Cells were separated by gentle pipetting and 
an adequate amount of the cell suspension was transferred to a new culture ware containing 
fresh medium. An overview about the used cell lines and the respective culture conditions 
is given in Table 8. The number of seeded cells and culture conditions used for in vitro 
assays are listed in Table 21. Depending on the experimental settings, human RMS cells 
were incubated with drugs (Western blot, Table 4), transfected and treated with 
Wnt3a conditioned medium (Wnt3a CM) as indicated in the respective experiments.  
Table 21: Cell culture conditions for in vitro assays 
Assay Format cells/well 
qRT-PCR 6-well plate 30 x 10
4
 
Western blot 10 cm-culture dishes 15 x 10
5
 
TOP/FOP reporter 96-well plate 5000 
Proliferation 96-well plate 6000 
Apoptosis 6-well plate 22 x 10
4
 









Immunofluorescence staining 4-chamber culture slides 4 x 10
4
 




5.2.2 Cryopreservation of eukaryotic cells 
For long-term storage eukaryotic cell lines were stored in liquid nitrogen. Cells were rinsed 
with PBS and detached as described above. Afterwards the cell suspensions were 
transferred into a 15 ml reaction tube, pelleted by centrifugation (5 min, 750 rpm, 4 °C) 
and resuspended in FCS supplemented with 5 % DMSO. Subsequently, 1 ml aliquots in 
cryo tubes were frozen in a Mr. Frosty freezing container at -80 °C. After 16 h the cells 
were transferred to liquid nitrogen.    
For thawing, the cells were rapidly warmed and transferred to 10 ml medium, pelleted 
(5 min, 750 rpm, 4 °C) and resuspended in fresh culture medium. Cells were transferred to 
the required cell culture plates or flasks and grown ON in an incubator. The next day, 
medium was refreshed to ensure a complete elimination of DMSO.  
5.2.3 Retroviral transduction of eukaryotic cells 
For generation of stable LEF1 knockdown (LEF1 KD) cell lines, RMS cells were either 
transduced with lentiviral pGIPZ vector containing the LEF1 silencing sequence or with 
the empty vector using the packaging cell line HEK293T (ATCC, Rockville, USA). For 
this purpose, HEK293T cells were transiently co-transfected with plasmids expressing the 
viral envelope and other viral proteins necessary for proper packaging and generation of 
functional virus particles. The stable transduction of the RMS cell lines was performed in 
collaboration with Prof. Dr. Tobias Pukrop and Dr. Florian Klemm at the Department of 
Hematology and Oncology, University Medical Center Göttingen.  
Stable cell lines were selected in medium with puromycin. The concentration of puromycin 
used for selection was 0.5 µg/ml for RMS-13 and 2 µg/ml for Rh41 and TE671. Since the 
pGIPZ vector expresses GFP, shRNA expressing cells could also be visualized and 
monitored directly by fluorescence.  
5.2.4 Transfection of eukaryotic cells 
RMS cells were transfected using the NEON Transfection System according to the 
manufacturer’s protocol. In brief, RMS cells were grown to 70-90 % confluence, harvested 
and counted. After washing, the cell pellet was resuspended in Resuspension Buffer R 
(included in the NEON Kit) with a final density of 4 x 10
6
 cells/ml. For transfection 
4 x 10
5
 cells were mixed with 5 µg siRNA or 6.3 µg plasmid DNA in a final volume of 




2 pulses, pulse time 30 msec. After 48 h the cells were collected by centrifugation (5 min, 
750 rpm, 4 °C) and used for subsequent experiments (i.e. for transient β-catenin 
knockdown and TOP/FOP reporter assay).  
5.2.5 Transient β-catenin knockdown (β-catenin KD) 
Knockdown of β-catenin (CTNNB1) in RMS cell lines was achieved by using a β-catenin-
specific siRNA pool (see Table 11) as described in Chapter 5.2.4. Scrambled siRNA was 
used as control siRNA (Table 11). Knockdown experiments were performed twice 
followed by qRT-PCR and Western blot analysis. For qRT-PCR analysis, 30 x 10
4
 
siRNA-transfected RMS cells were seeded, incubated in 6-well plates for 24 h and RNA 
was isolated afterwards. 
5.2.6 TOP/FOP reporter assay 
Canonical β-catenin-driven WNT signaling activity in RMS cell lines was measured after 
transfection with 3 µg SuperTOPFlash (TOP) containing multiple TCF/LEF-binding sites 
or its negative control vector SuperFOPFlash (FOP) as described above. Renilla reporter 
plasmid pRL-CMV was used for normalization. Co-transfection with 3 µg pCl-neo-
β-cateninS33Y served as positive control. Consequently, 5000 transfected cells/well were 
seeded in 96-well plates. After 24 h, the cells were incubated for additional 48 h with 
Wnt3a CM. Luciferase activity was measured in triplicates for each condition using the 
Dual-Luciferase reporter assay system (see below). 
5.2.7 Dual-Luciferase assay 
Dual-luciferase assays of RMS cells were performed in 96-well plates using the 
Dual-Luciferase reporter assay system according to the manufacturer’s instruction. In brief, 
the cells were washed and lysed in 20 μl 1 x passive lysis buffer (PLB) per well. The plates 
were incubated on an orbital shaker for 15 min at 250 to 300 rpm and RT. Afterwards the 
plates were frozen and stored at -80 °C until use. LAR II and Stop’n’Glo solutions were 
prepared and stored as described in the manufacturer’s instruction. Prior to the 
measurement the LAR II and Stop’n’Glo solutions were allowed to equilibrate to RT for at 
least 15 min. The measurement was conducted on a Synergy MX luminometer. The firefly 




5.2.8 Generation of Wnt3a conditioned medium 
Wnt3a CM or respective control CM were obtained from murine L-cells stably transfected 
with Wnt3a expression plasmid or from non-transfected L-cells, respectively. Culture 
conditions are given in Table 8. Wnt3a CM and control CM were prepared as described by 
a protocol provided by ATCC (Willert et al., 2003). Briefly, the cells (for Wnt3a CM and 
control CM) were split 1:10 and cultured in 10 ml fresh medium without G 418 for 
four days. The medium was removed, clarified with a 0.2 µm sterile filter and placed to 
4 °C. Fresh medium (10 ml) was added for another three days and processed as described. 
The first and second batches of conditioned media were pooled and stored at 4 °C.   
5.2.9 Proliferation assay 
Cellular proliferation was analyzed using the 5-Bromo-2-Deoxyuridine (BrdU) cell 
proliferation kit according to the manufacturer’s instructions. Measurement of 
BrdU incorporation was determined by luminescence in a microplate reader. In brief, 
6000 cells/well were seeded in 96-well plates. After 12 h, the cells were incubated for 22 h 
with medium supplemented with 10 µM BrdU. After fixation of the cells and denaturation 
of the DNA for 30 min, peroxidase coupled BrdU antibody (anti-BrdU-POD) was added 
for 1 h. After thorough washing, peroxidase substrate was added to the plates. All samples 
were measured in triplicates. The data was analyzed and plotted using Microsoft Excel and 
GraphPad Prism 6 software. 
5.2.10 Apoptosis assay 
Cellular apoptosis was analyzed by flow cytometry after staining of the cells with 
allophycocyanin (APC) AnnexinV and 7-Amino-Actinomycin D (7-AAD). 22 x 10
4
 
cells/well were seeded in 6-well plates. After 12 h, cells were washed with PBS, detached 
with 1 ml accutase/well, transferred into a 15 ml reaction tube and pelleted by 
centrifugation (5 min, 1000 rpm, 4 °C). After washing with PBS the cells were incubated 
with 100 μl AnnexinV binding buffer supplemented with 2 μl APC AnnexinV for 10 min, 
followed by incubation with 7-AAD for 5 min at RT and under light exclusion. Finally, 
300 µl AnnexinV binding buffer was added to the cell suspension and measurement of 
fluorescence was performed on a LSRII flow cytometer. All samples were measured in 





5.2.11 Migration assay 
For cell migration assay 10
5
 cells were seeded onto membrane-inserts (translucent 
track-etched polyethylene terephthalate [PET] membranes) with 8 µm pores and incubated 
for 18 h in a 24-well-plate in 500 µl medium. Afterwards the membrane-inserts were 
transferred into a new 24-well-plate containing 5 µM calcein in 500 µl fresh medium and 
the cells were stained for 1 h at 37 °C. After washing with PBS and removing of cells on 
top of the membrane (cells which had not migrated), the cells at the bottom of the 
membrane were analyzed. For this purpose, 6-7 consecutive pictures at 10-fold 
magnification were taken of each well and cells were counted manually using 
AlphaView Q Imaging software.  
To exclude that cellular proliferation influenced the results, 10
5
 cells/well were seeded 
simultaneously in 24-well-plates and cultured for 18 h. Afterwards, cells were washed with 
PBS, detached with 0.5 ml TrypLE Express/well, transferred into a 15 ml reaction tube and 
pelleted by centrifugation (5 min, 750 rpm, 4 °C). After removal of the supernatant, the 
pellet was resuspended in 1 ml culture medium. To determine cell viability, the cell 
suspension was diluted 1:10 with trypan blue solution and cells were counted using a 
Neubauer counting chamber.  
All measurements were performed in duplicates and analyzed and displayed by Microsoft 
Excel and GraphPad Prism 6. 
5.2.12 Invasion assay 
Invasion was measured together with Matthias Schulz (Department of 
Hematology/Medical Oncology, University Medical Center Göttingen) by assessment of 
the RMS cell migration rate using an artificial basement membrane in a modified Boyden 
chamber as described (Hagemann et al., 2004).  
The membrane consisted of polycarbonate (10 µm pore diameter) and was coated on ice 
with Matrigel (ECM gel) diluted 1:4 in serum-free RPMI. 10
5
 RMS cells in 500 µl medium 
were seeded into the upper well of the chamber, while the lower well was filled up to the 
top with RPMI. 10 % FCS served as a chemoattractant. After 96 h, the floating cells in the 
lower well were collected, pelleted by centrifugation, resolved in 1 ml PBS and counted 






 cells/well were seeded in 24-well-plates in medium and cultured for 
96 h to analyze cell proliferation as described above in Chapter 5.2.11.  
All samples were measured in duplicates. Data analysis was performed with Microsoft 
Excel and GraphPad Prism 6. 
5.3 Protein chemistry and immunohistochemistry 
5.3.1 Protein isolation from cell culture 
For protein isolation from cultured cells, the cells were washed and scraped in 2 ml cold 
PBS using a cell scraper and centrifuged (5 min, 1000 rpm, 4 °C). After removal of the 
supernatant, the pellet was resuspended in 200 to 500 μl PBS and transferred into a 1.5 ml 
reaction tube followed by a second washing step. Subsequently, the pellet was shock 
frozen in liquid nitrogen, thawed on ice for 20 min and incubated with 40-200 µl lysis 
buffer supplemented with 500 μM PMSF and 2 mM DTT for additional 30 min on ice. 
Finally, the lysates were centrifuged (30 min, 13000 rpm, 4 °C) and the supernatant 
containing the soluble proteins was transferred to a new 1.5 ml reaction tube and stored 
at -80 °C until use. The protein concentration was measured using the Pierce BCA Protein 
Assay Kit according to manufacturer’s instructions. 
5.3.2 Western blot 
For Western blot analysis protein lysates were denatured in SDS loading buffer for 5 min 
at 96 °C and 450 rpm in a shaker. The exception was the analysis of WNTA protein that 
was carried out under non-denaturing conditions with β-mercaptoethanol-free loading 
buffer. Afterwards protein samples were loaded on 4-12 % Bis-Tris Gels (NuPAGE 
Novex) and electrophoresed in running buffer (NuPAGE MES SDS) at 160 mA, 160 V 
and 100 W for 1.5-3 h. A protein marker (SeeBlue Plus2 Pre-Stained) was loaded to allow 
an accurate estimation of the molecular weight of the proteins. Next, the proteins were 
transferred from the gel onto a nitrocellulose membrane by wet blotting in blotting buffer 
at 100 V, 500 mA and 100 W for 80 min in a cold room. For visualization of proteins, the 
membrane was blocked with 5 % (w/v) milk powder/TBST for 1-1.5 h at RT. After 
washing three times in TBST for 10 min, the membrane was incubated with primary 
antibodies (see Table 13) at 4 °C ON. The next day, the membrane was washed again 
three times for 10 min in TBST and subsequently incubated with adequate HRP 




step in TBST, the membrane was incubated with the detection reagent ECL for 1 min at 
RT. Then the ECL was removed and detection was accomplished with a Fluorchem Q 
Imaging system. All primary antibodies were dissolved in BSA-azide/TBST and all 
secondary antibodies were dissolved in 5 % milk powder/TBST. 
5.3.3 Haematoxylin eosin (HE) staining 
For HE staining, mouse tissue fixed in 4 % PFA was embedded in paraffin, cut into 4-5 μm 
sections and mounted onto glass slides. The sections were deparaffinized two times in 
xylene for 10 min and subsequently rehydrated by descending ethanol solutions (99 % to 
70 %). After short washing with ddH2O, slides were stained in haematoxylin solution for 
15 min and washed with lukewarm tap water for at least 2 min. Slides were then placed in 
1 % eosin solution for a maximum of 20 sec and washed again with ddH2O. Then the 
sections were dehydrated using ascending ethanol solutions (70 % to 99 %) and placed 
again in xylene. Afterwards the sections were mounted in Pertex and dried at 55 °C for 
20 min. 
5.3.4 Immunohistochemical staining of tissues 
Staining of a TMA consisting of 25 ARMS and 100 ERMS samples (biopsies from the 
Paediatric Tumor Register, Kiel, Germany) was performed in collaboration with Dr. Katja 
Simon-Keller at the Institute of Pathology, University Medical Center Mannheim. The 
RMS biopsies were embedded in paraffin and sectioned at 5 µm. After quality control, 
41 ERMS and 7 fusion-positive ARMS samples were evaluable. Immunohistochemistry 
was performed as described in detail elsewhere (Zeitler et al., 2004) using the following 
chemicals and reagents: antigen retrieval in antigen retrieval solution pH 6.0 or pH 9.0; 
blocking of endogenous peroxidase and detection of bound antibodies by the 
immunoperoxidase/DAB-based detection system (Table 5). Used primary antibodies are 
shown in Table 14.  
5.3.5 Immunofluorescence staining 
5.3.5.1 Immunofluorescence staining of cryosections 
Immunofluorescence staining of RMS cryosections derived from the CAM assay was 
performed in collaboration with Prof. Dr. Jörg Wilting at the Institute of Anatomy and Cell 
Biology, University Medical Center Göttingen. After incubation for 1 h with blocking 
reagent (PBS, 1 % BSA), sections were incubated ON with the primary anti-HLA-A,B,C 




in antibody solution mixed with DAPI (1:10000). After every step specimens were rinsed 
twice with PBS. Samples were mounted with Fluoromount-G and dried ON at RT. Stained 
specimens were studied with Zeiss Axio Imager.Z1 (Carl Zeiss Göttingen) and filter sets 
38HE, 43 and 49. Used primary antibodies and corresponding secondary antibodies are 
shown in Table 14.  
5.3.5.2 Immunofluorescence staining of cells 
For immunofluorescence staining of cells, 4 x 10
4
 cells/chamber were seeded in 4-chamber 
culture slides and after 24 h incubated with Wnt3a CM or control CM for additional 3 h. 
Cells grown on 4-chamber culture slides were fixed with 2 % PFA at RT for 10 min and 
with methanol at -20 °C for additional 5 min. Fixed cells were washed twice in PBS. After 
permeabilization with 0.5 % Triton X-100 (in PBS) for 5 min at RT, unspecific antigens 
were blocked with 4 % BSA (in PBS) for 1 h in a moist chamber and slides were rinsed 
twice with PBS. Subsequently, the cells were stained with anti-β-catenin antibody ON at 
4 °C followed by staining with TRITC-conjugated anti-mouse antibody as secondary 
antibody for 1 h at RT. Finally, cells were mounted with ProLong Gold antifade reagent 
with DAPI and analyzed by fluorescence microscopy (Olympus BX 60, equipped with 
U-RLF-T). Serial pictures at 60-fold magnification were taken for each chamber of the 
slides and fluorescence images were acquired by using a Color View camera operated by 
CellSens software. Two independent experiments were performed. Used primary 
antibodies and corresponding secondary antibodies are shown in Table 14.  
5.4 In vivo tumor model and animal experiments 
5.4.1 Chorio-allantoic membrane (CAM) assay 
The CAM assay was performed in collaboration with Prof. Dr. Jörg Wilting at the Institute 
of Anatomy and Cell Biology, University Medical Center Göttingen. All experiments were 
performed according to the guidelines of the European Parliament (2010/63/EU) and the 
council for the protection of animals in science (§14 TierSchVersV). 
Fertilized White Leghorn chick eggs were incubated at 80 % relative humidity and 
37.8 °C. The eggs were windowed at day 3 of chick development and the window was 
sealed with cellotape. At day 10 of chick development, 2 x 10
6 
RMS-13 cells were 
resuspended in 50 % RPMI-medium and 50 % Matrigel, incubated for 30 min at 37 °C, 




seven days (day 17 of chick development), fixed in 4 % PFA for 20 min, washed twice in 
PBS and transferred into 10 % sucrose for 3 h at 4 °C and afterwards into 30 % sucrose 
ON at 4 °C. The next day, the tumors were embedded in tissue freezing medium and cut 
with a cryotome into 14 μm thick sections.  
Tumors and tumor cells were visualized by intravital GFP imaging at day 3 and 7 post 
inoculation. Cryosections of CAM-bearing tumors were analyzed by immunofluorescence 
staining (see Chapter 5.3.5.1).   
5.4.2 Breeding of mice 
Mice were bred and housed in the animal facility of the Institute of Human Genetics, 
University of Göttingen, Germany. Animals were kept in Makrolon cages type II and III. 
The animals were supplied with rodent pellets and tap water ad libitum and maintained at a 
12 h light-dark cycle (light period: 6 a.m.–6 p.m.), a temperature of 20±2 °C and a relative 
humidity of 50±10 %.  
5.4.3 Tissue biopsies and genotyping of mice 
To identify the genotype and to mark the mice, tail clipping (from the tip of the tail) and 
ear marking of weaned 4 weeks old mice was done by the staff of the animal facility. 
Genotyping was performed by isolation of gDNA from tail tissue or ear punches followed 
by PCR using the primers and conditions shown in Table 9 and Table 18. 
5.4.4 Monitoring of RMS bearing mice 
In order to record the occurrence of RMS, mice were monitored once a week by manual 
palpation and careful viewing. If possible the animals were kept for at least 250 days after 
birth. Then all mice were sacrificed and autopsied. Animals that had lost 20 % of their 
body weight or were at poor general conditions or carried tumors exceeding a size of 1 cm 
were sacrificed immediately and autopsied.  
5.4.5 Preparation and isolation of RMS 
Tumors, skeletal muscle, cysts and irregular or suspicious tissues were excised and 
carefully washed with PBS. Part of the tumor and reference tissues was formalin fixed and 
embedded in paraffin for HE staining. Remaining tumor tissue and skeletal muscle were 






Unless indicated otherwise, statistical and graphical analyses were conducted using the 
programs GraphPad Prism 6, MS Office Excel or Statistica 10. Data were considered 
significant if P values were <0.05. When comparing two samples, statistical differences 
were analyzed using Student’s t-test or unpaired, non-parametric t-test (Mann-Whitney) as 
indicated in the respective experiments. Correlation of mRNA expression levels in primary 
human RMS samples was tested by a parametric Pearson test and a non-parametric 
Spearman test. For the in vivo data, statistical significance of the RMS-free survival was 







The results of this thesis are divided into two parts. The first part focuses on the function of 
LEF1 and β-catenin dependent WNT signaling in RMS pathogenesis. The second part is 
dedicated to the role of LEF1 in context with non-canonical WNT5A signaling in RMS. 
6.1 LEF1 and β-catenin expression in primary human RMS 
To examine the role of LEF1 and β-catenin in primary human RMS, a TMA and qRT-PCR 
analysis on fresh frozen samples were performed in collaboration with Dr. Katja 
Simon-Keller and Prof. Dr. Alexander Marx from the Institute of Pathology, University 
Medical Center Mannheim. Finally, 41 ERMS from the TMA and 10 fresh-frozen ERMS 
samples could be analyzed, whereas only 7 ARMS from the TMA, but also 10 fresh-frozen 
ARMS samples were available for analysis. All ARMS samples were fusion-positive. 
The results of the TMA revealed that LEF1 can be highly expressed in fusion-positive 
ARMS and ERMS. 44 % of the RMS samples were positive for LEF1, however to a 
variable extend with some individual tumors showing a very heterogeneous LEF1 
distribution (Figure 3A). Consequently, the studied samples were subdivided into low, 
intermediate or high expressers according to the scoring range of <50, 50-150 or >150, 
respectively. The score was calculated by multiplying the percentage of positive cells by 
the intensity of the staining (weak staining: 1, moderate staining: 2, or strong staining: 3) 
(reviewed in Fedchenko et al., 2014). No ARMS with a high LEF1 score was detected and 
in general the LEF1 score was higher in ERMS compared to ARMS, however without 
reaching significance. LEF1 protein was exclusively found in the nucleus. Likewise, 
heterogeneous overexpression of LEF1 was also seen on mRNA level in 10 human fusion-
positive ARMS and 10 human ERMS compared to normal skeletal muscle (n=4; Figure 
4A). Similar to the results from the TMA, the ERMS samples showed generally higher 
LEF1 mRNA levels than ARMS samples, however without reaching significance.  
When β-catenin expression was analyzed, 48 % of the RMS samples were stained positive 
(Figure 3B). Signals were detected in the cytoplasm but absent in the nuclei with the 
exception of one ERMS case that additionally showed nuclear β-catenin expression. On 
mRNA level all RMS expressed unequivocal high levels of CTNNB1 when compared to 
normal muscle (Figure 4B), but no correlation with LEF1/LEF1 expression was observed 





Figure 3: Immunohistochemical analyses of LEF1 and β-catenin in human RMS biopsies. 
Representative immunohistochemistry staining of (A) LEF1 and (B) β-catenin in primary human 
fusion-positive ARMS (n=7) and human ERMS (n=41). Results were scored by multiplying the percentage 
of positive cells by the intensity of the staining to subdivide studied samples into low, intermediate and high 
expressers. The proportion of LEF1-and β-catenin-positive cells as well as the intensity of the staining was 






































Figure 4: qRT-PCR analyses of LEF1, CTNNB1 and AXIN2 in human RMS biopsies. (A) LEF1, 
(B) CTNNB1 and (C) AXIN2 expression levels analyzed by qRT-PCR in fresh-frozen biopsies of human 
fusion-positive ARMS (n=10) and human ERMS (n=10) compared to normal muscle (n=4). Gene expression 
levels were normalized to GAPDH expression levels. Bars, 95 % confidence intervals and mean values; 
**P<0.01 by Mann-Whitney t-test. 
 
Furthermore, mRNA expression of AXIN2 – the major downstream target of β-catenin 
dependent WNT signaling – was significantly downregulated in both ARMS and ERMS 
compared to normal skeletal muscle (Figure 4C).  
In summary, approximately half of fusion-positive ARMS and ERMS samples express 
nuclear LEF1 and cytoplasmatic β-catenin with however variable intensity and lack of any 
correlation. The common absence of nuclear β-catenin and of AXIN2 expression suggests 
that canonical WNT signaling in general is not active in RMS. 
6.2 In vivo effect of Wnt3a on RMS development 
To get an impression whether canonical Wnt signaling may actually not influence RMS 
growth and progression in vivo, a genetic approach was conducted using Ptch
del/+ 
mice that 
develop RMS with high incidence. For this purpose, Ptch
del/+ 
mice were crossed with 
Wnt
vt/vt 
(vestigial tail) mice. Wnt
vt/vt
 mice carry a hypomorphic Wnt3a allele and therefore 




 mice and the 




 were monitored weekly for a minimum of 
250 days to record RMS formation. Afterwards mice were sacrificed and autopsied. All 
tumors were removed and histologically evaluated using HE-stained paraffin sections. As 
shown in Table 22 and Figure 5A, the overall RMS incidence (38 % versus 31 %) and the 
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 40 15 (38 %) 206 2 (5 %) 
 
 









 mice (solid line). All mice were monitored for a 
minimum of 250 days, if possible. Each event represents the detection of the first RMS in a mouse. 
According to the log-rank test that was used to analyze differences in the survival curves the P-value was 









 mice. Statistical significance was analyzed by Chi-square (χ
2
) test (P=0.626). 












































 mice (5 %=2/40 versus 
14 %=5/36 in control mice; Table 22) this difference was not significant according to 
Chi-square testing (Figure 5B).  
This indicates that Wnt3a-driven canonical Wnt/β-catenin signaling does not play a 
prominent role in RMS pathogenesis in mice. The data have been published in Nitzki et al., 
2016.  
6.3 Generation of stable LEF1 KD RMS cell lines 
Since WNT/β-catenin driven signaling activity apparently did not play a prominent role in 
RMS pathogenesis, we next analyzed the function of LEF1 in RMS in more detail. For this 
purpose, the human ARMS cell lines Rh41 and RMS-13 and the ERMS cell line TE671 
were used. All of these RMS cell lines express full-length LEF1 isoform of 44 kDa, 
whereas the truncated isoforms lacking the β-catenin binding site 31 kDa and 23 kDa 
(see Van de Wetering et al., 1996; Hovanes et al., 2001) were merely detected (Figure 6A). 
Western blot was also performed with the human breast cancer cell line SKBR3, which 
overexpresses LEF1, and with the LEF1-negative human Jurkat T cells. 
Subsequently, LEF1 was stably deleted in the RMS cell lines by retroviral shRNA transfer 
in collaboration with Prof. Dr. Tobias Pukrop and Dr. Florian Klemm, Department of 
Haematology/Medical Oncology, University Medical Center Göttingen. As verified on 
protein level, LEF1 was efficiently deleted in all RMS LEF1 KD cell lines when compared 
to the respective control transduced (control) cells (Figure 6A).  
The stable LEF1 KD in the cell lines resulted in a significant downregulation of the LEF1 
target AXIN2 in RMS-13 cells when compared to control cells that were set to 1 (Figure 
6B). Interestingly, the LEF1 target c-MYC was significantly increased in RMS-13 LEF1 
KD and Rh41 LEF1 KD cells (Figure 6B) in comparison to the respective control cells. No 
significant effects of the LEF1 KD on the expression of the two mentioned genes were 
seen in TE671 cells. 
In brief, LEF1 has different effects in the three used cell lines. Thus, it blocks the 
expression of c-MYC in both ARMS cell lines but not in TE671 cells, and activates AXIN2 





Figure 6: Generation of stable LEF1 knockdown (LEF1 KD) RMS cell lines and expression analyses of 
WNT target genes. (A) Representative LEF1 Western blot of the human ARMS cell lines Rh41 and 
RMS-13 and the human ERMS cell line TE671. The cell lines were either untransduced (ut) or stably 
transduced with empty vector control (control) or LEF1 shRNA (LEF1 KD). HSC-70 expression levels 
served as loading control and protein ladder is shown for estimation of protein size. SKBR3 and 
Jurkat T cells were used as positive and negative controls. (B) mRNA levels of AXIN2 and c-MYC in 
Rh41 LEF1 KD, RMS-13 LEF1 KD and TE671 LEF1 KD cells are shown as fold change to the respective 
control cells that were set to 1 (dashed line). Gene expression levels were normalized to 18S rRNA 
expression levels. Data represent mean+SEM of three independent experiments performed in duplicates and 
measured in triplicates; *P<0.05, ***P<0.001 by Students t-test. 
 
















































































6.4 Analysis of canonical WNT signaling activity in human RMS cell lines 
We next investigated whether β-catenin driven WNT signaling activity can be activated in 
RMS cell lines and if LEF1 is important for its maintenance. For this purpose, the stable 
RMS LEF1 KD cells and their respective control cells were transfected with the 
SuperTOPFlash (TOP) plasmid containing multiple TCF/LEF-binding sites or its negative 
control vector SuperFOPFlash (FOP) along with Renilla reporter plasmid for 
normalization. WNT signaling was activated by incubation with Wnt3a CM for 48 h. As a 
positive control, the pCl-neo-β-cateninS33Y (β-catS33Y) plasmid was co-transfected. 
Moreover, analyses of AXIN2 transcription levels served as approved readout for active 
canonical WNT signaling.  
As shown in Figure 7, AXIN2 mRNA expression was significantly increased after 
treatment with Wnt3a CM for 48 h in all cell lines when compared to control CM. 
However, the TOP reporter was not significantly activated by Wnt3a in the ARMS cell 
lines Rh41 and RMS-13. Thus, and as shown in Figure 8, TOP reporter activity was only 
marginally induced in Rh41 control (1.7-fold) and Rh41 LEF1 KD cells (2.7-fold) by 
Wnt3a CM in comparison to control CM incubation (that was set to 1). This was similar in 
RMS-13 LEF1 KD cells (3-fold induction in response to Wnt3a CM), whereas RMS-13 
control cells did not show any luciferase induction in response to Wnt3a when compared to 
control CM treated cells. In contrast, TE671 control and LEF1 KD cells showed a more 
than 10-fold induction of TOP activity after Wnt3a CM treatment. Co-transfection with 
activated β-catenin (β-catS33Y) revealed strong luciferase induction in all settings, except 
in RMS-13 LEF1 KD cells.   
Incubation with Wnt3a CM after FOP-transfection did not induce luciferase activity in any 
of the cell lines (Figure 9). Surprisingly, co-transfection of FOP-transfected TE671 control 
cells with β-catS33Y induced luciferase activity (1.4-fold; P=0.041) when compared to 
solvent. The reason for this induction is not clear. However, since the luminescence 
activity following β-catS33Y/TOP-transfection was 43 times higher than the activity of 





Figure 7: Activation of β-catenin dependent WNT signaling in human RMS cell lines. qRT-PCR 
analysis of AXIN2 in Rh41, RMS-13 and TE671 control and the respective LEF1 KD cells after incubation 
with Wnt3a CM for 48 h in comparison to the control CM treated cells. AXIN2 expression was normalized to 
18S rRNA expression levels. Data represent two independent experiments performed in duplicates and 














































































































































































































Figure 8: β-catenin driven WNT signaling activity in RMS cell lines. To analyze β-catenin dependent 
WNT signaling activity Rh41, RMS-13 and TE671 control and LEF1 KD cells were transfected with TOP 
plasmid containing multiple TCF/LEF-binding sites. Luciferase activity was measured five days after 
transfection in response to Wnt3a CM or control CM. Data show the 95 % confidence intervals of two 
independent experiments performed in triplicates and are depicted as fold change luciferase activity to the 
respective control CM treated cells that was set to 1 (dashed line). Statistical significance was tested using 



































































































































































































































































Figure 9: Control experiments of data shown in Figure 8. Rh41, RMS-13 and TE671 control and 
LEF1 KD cells were transfected with FOP plasmid containing mutated and thereby inoperable 
TCF/LEF-binding sites as negative control for data shown in Figure 8. Luciferase activity was measured 
five days after transfection in response to Wnt3a CM or control CM. Data show the 95 % confidence 
intervals of two independent experiments performed in triplicates and are depicted as fold change luciferase 
activity to the respective control CM treated cells that was set to 1 (dashed line). Statistical significance was 



















































































































































































































































In order to evaluate to which extend the LEF1 KD influences Wnt3a-mediated TOP 
induction, the values from the TOP luciferase activity of the LEF1 KD cells were 
normalized to that of the respective control cells (that were set to 1, Figure 10A). 
Importantly, the LEF1 KD in all TOP-transfected RMS cell lines did not significantly 
influence reporter activity when compared to respective control cells after incubation with 
Wnt3a, i.e. no significant alterations in luciferase activity was obtained that could be 
ascribed to LEF1 KD (Figure 10A). Furthermore, none of the settings had any effect on the 
luciferase activity in FOP-transfected RMS LEF1 KD cells compared to FOP-transfected 
control cells (Figure 10B).  
The TOP/FOP reporter assay was also performed in the presence of the GSK3β inhibitor 
LiCl that – similarly to Wnt3a – activates canonical WNT signaling. Notably, the results 
using LiCl were conform to those after incubation with Wnt3a CM in RMS-13 and TE671 
control and LEF1 KD cells. However, the data obtained from Rh41 control and LEF1 KD 
cells were rather inconsistent, making it impossible to analyze them. Therefore, the results 
regarding LiCl incubation are not shown in this thesis.  
To sum up, the data show that despite an upregulation of AXIN2 – as readout for active 
canonical WNT signaling – Wnt3a stimulation does not change TOP reporter activity in 
Rh41 and RMS-13 control cells but induces it in TE671 control cells. Thus, canonical 
WNT signaling appears to be functionally active in the mentioned ERMS cell line but not 
in both ARMS cell lines. Furthermore, the data indicate that LEF1 is not necessary for 
activation of the TOP reporter, i.e. it is dispensable for β-catenin driven WNT signaling 
activity in all three RMS cell lines. Due to the fact that β-catS33Y did not induce signaling 
activity in RMS-13 LEF1 KD cells, it can be further speculated that LEF1 depletion 





Figure 10: LEF1-dependent modulation of β-catenin driven WNT signaling activity in RMS cell lines. 
Data of (A) TOP-transfected and (B) FOP-transfected Rh41 LEF1 KD, RMS-13 LEF1 KD and 
TE671 LEF1 KD cells after incubation with control CM and Wnt3a CM for 48 h are calculated as fold 
change luciferase activity in comparison to the respective TOP-or FOP-transfected control cells that were set 
to 1 (dashed line). Data show the 95 % confidence intervals of the same two independent experiments shown 































































































































































































































6.5 Analysis of β-catenin functionality and LEF1-dependent expression of TCF 
factors in RMS cell lines 
In the ARMS cell lines Rh41 and RMS-13, AXIN2 expression was induced by Wnt3a CM 
despite lack of TOP reporter activity (see Figure 7 and Figure 8). Thus, the expression of 
AXIN2 seems to be independent of β-catenin and regulated by other factors. Since 
β-catenin in the analyzed cell lines was not mutated (as analyzed by our collaborator 
Dr. Katja Simon-Keller; data not shown), the lack of TOP reporter activity in ARMS cells 
also suggested that the parental RMS-13 and Rh41 cells may possess a mechanism that 
prevents endogenous β-catenin from binding to the reporter plasmid. For instance, it is 
possible that β-catenin is retained in the plasma membrane or cytoplasm (for review see 
Kimelman et al., 2006). Finally, the fact that activated β-catS33Y did not induce signaling 
activity in RMS-13 LEF1 KD cells (see Figure 8) additionally argued for a factor that 
prevents β-catS33Y from binding to the TCF-binding sites of the reporter plasmid after 
LEF1 depletion. 
To answer these issues, we analyzed whether β-catenin was able to translocate to the 
nucleus after stimulation with Wnt3a (see Chapter 6.5.1). Moreover, the expression of the 
other TCF factors that also interact with β-catenin and generally can activate (TCF1 and 
TCF4) or inhibit (TCF3 and TCF4) canonical WNT signaling (Cadigan et al., 2012; Shah 
et al., 2015) was examined in dependency of LEF1 (see Chapter 6.5.2). 
6.5.1 Effect of Wnt3a on subcellular localization of β-catenin in RMS cell lines 
We first analyzed whether activation of canonical WNT signaling resulted in translocation 
of β-catenin to the nucleus. For this purpose, the cells were stimulated with Wnt3a CM 
for 3 h and after that stained for β-catenin immunofluorescence (red) and counterstained 
with DAPI (blue) to determine β-catenin subcellular localization. Merged images of 
β-catenin immunofluorescence and DAPI staining are shown in Figure 11. Compared to 
the control CM, immunofluorescence staining of the ERMS cell line TE671 demonstrated 
predominant nuclear accumulation of β-catenin upon Wnt3a treatment. In contrast, nuclear 
β-catenin was never detectable in RMS-13 cells, whereas a very weak but distinct nuclear 
β-catenin staining was detected in approximately 10 % of Rh41 cells after incubation with 
Wnt3a CM (Figure 11). This is similar to the results of the TOP/FOP reporter assay that 
showed a 1.3-fold and 1.7-fold induction of TOP activity in RMS-13 and Rh41 control 





Figure 11: Localization of β-catenin after Wnt3a stimulation in RMS cell lines. Representative images of 
β-catenin immunofluorescence staining (red) in Rh41, RMS-13 and TE671 control transduced (control) cell 
lines cultured in Wnt3a CM or control CM for 3 h. DAPI was used to stain cell nuclei (blue). Images (60-fold 















































































To sum up, the immunofluorescence staining support the hypothesis that endogenous 
β-catenin in Rh41 and RMS-13 is hold back at the plasma membrane or in the cytoplasm 
(Figure 11). This is in contrast to the ERMS cell line TE671, in which canonical WNT 
signaling is functionally active (see Figure 8 and Figure 11). 
6.5.2 Effect of LEF1 KD on the expression of TCF factors in RMS cell lines 
Next, the influence of LEF1 on the expression of TCFs was examined by qRT-PCR in 
collaboration with Dr. Katja Simon-Keller at the Institute of Pathology, University Medical 
Center Mannheim. Our data reveal that all TCF factors were significantly upregulated in 
Rh41 LEF1 KD cells, whereas all of them were significantly downregulated in 
RMS-13 LEF1 KD cells (Figure 12) when compared to the respective control cells (that 
were set to 1). In TE671 LEF1 KD cells, we did not find any significant changes in 
comparison to control cells. 
 
Figure 12: LEF1-dependent expression of TCF factors in RMS cell lines. Expression of TCF1, TCF3 and 
TCF4 in Rh41 LEF1 KD, RMS-13 LEF1 KD and TE671 LEF1 KD are shown as fold expression to the 
respective control cells that were set to 1 (dashed line). Gene expression levels were normalized to GAPDH 
expression levels. Data represent mean+SEM of four independent experiments measured in triplicates; 
*P<0.05, **P<0.01, ***P<0.001 by Students t-test. 
 
Together, LEF1 rather suppresses the expression of TCFs in Rh41 cells, whereas it induces 
TCF factors in RMS-13 cells. The extreme downregulation of all TCFs upon LEF1 
depletion in RMS-13 cells may be the reason for the lack of TOP activation in β-catS33Y-
















































































6.6 Effects of LEF1 KD on cellular processes in RMS cell lines 
The stably transduced RMS LEF1 KD cell lines were also analyzed with respect to 
proliferation, apoptosis and their migratory and invasive properties.  
6.6.1 Effect on proliferation  
The LEF1 KD increased the proliferative capacity of all three RMS cell lines (Figure 13A). 
In Rh41 and RMS-13 LEF1 KD cells, the proliferation rate was significantly elevated by 
approximately 10 % and 50 %, respectively, when compared to control transduced cells. In 
the ERMS cell line TE671, LEF1 KD also resulted in a 10 % increase in 
BrdU incorporation when compared to the control, however without reaching significance.  
6.6.2 Effect on apoptosis 
LEF1 KD did not provoke any significant differences in the number of apoptotic cells in 
Rh41 and TE671 cells when compared to the respective control cells (Figure 13B). In 
contrast, the LEF1 KD in RMS-13 significantly decreased the number of AnnexinV 
positive i.e. apoptotic cells by more than 60 % in comparison to control cells.  
6.6.3 Effect on migration and invasion 
In RMS-13, the stable LEF1 KD resulted in a significant increase of the number of cells 
that migrated trough the membrane inserts or invaded the Matrigel in the Boyden chamber 
invasion assay (Figure 13C, D). Thus, the LEF1 KD in RMS-13 increased the migratory 
and invasive capacity approximately 8 times and 1.5 times, respectively, in comparison to 
RMS-13 control cells. In contrast, LEF1 KD had no impact on the migration rate of Rh41 
and TE671 cells, but led to a significant decrease or increase of cell invasiveness in 
Rh41 LEF1 KD and TE671 LEF1 KD cells, respectively, when compared to control cells 
(Figure 13C, D).  
In summary, the results reveal that the effect of LEF1 KD on cellular processes is 
heterogeneous depending on the individual cell line. Nevertheless, and despite the fact that 
LEF1 KD decreases the invasive capacity of Rh41 cells, the data show that depletion of 
LEF1 in general results in increased RMS proliferation, and further can enhance 
migratory/invasive properties and also inhibit apoptosis. In other words, the presence of 





Figure 13: LEF1-dependent regulation of proliferation, apoptosis, migration and invasiveness of RMS 
cell lines. (A) Proliferation, (B) apoptosis, (C) migratory capacity and (D) invasiveness of the Rh41, RMS-13 
and TE671 control and LEF1 KD cells were analyzed by BrdU incorporation assay, FACS, trans-well 
migration and Boyden chamber assay. The values of the respective control cells were set to 100 % (black 
bar). Data represent mean+SEM of two independent experiments performed in triplicates 
(BrdU incorporation assay, migration assay for RMS-13) or duplicates (apoptosis, invasion and migration 











































































































































6.6.4 Effect of LEF1 KD on RMS growth and aggressiveness in vivo 
To confirm that LEF1 is associated with a less aggressive phenotype, a CAM assay was 
performed, which is an established in vivo model for tumor growth and invasiveness. To 
this end, RMS-13 LEF1 KD and RMS-13 control cells were seeded on the CAM of 
chicken embryos and were allowed to form tumors for seven days. Due to stable 
transduction with the lentiviral pGIPZ vector that expresses GFP the growth and invasive 
potential of the cells could be visualized by fluorescence.  
Three days after inoculation, the RMS-13 LEF1 KD cells have formed larger tumors in 
comparison to the control cells (Figure 14A). Seven days after inoculation, LEF1 KD 
tumors showed massive infiltration of tumor cell clusters into the surrounding stroma. This 
was accompanied by destruction of vessels and hemorrhage, which was not observed in the 
control tumors (Figure 14B, C). Moreover, whole-mount GFP imaging revealed that 
RMS-13 LEF1 KD cells migrated long distances from the primary tumor (Figure 14C). 
Indeed, HLA immunofluorescence staining detected human MHC-positive 
RMS-13 LEF1 KD cells in the stroma of the CAM several millimeters apart from the 
primary tumor (Figure 14D).  
To sum up, the results from the in vivo CAM assay demonstrate that LEF1 inhibits growth 
as well as the migratory and invasive properties of RMS-13 cells. This is in agreement with 






Figure 14: LEF1-dependent regulation of proliferation and invasion of RMS-13 cell line in the CAM 
assay. Shown are representative whole-mount images of (A) RMS-13 control tumors (n=7) and 
RMS-13 LEF1 KD tumors (n=7) at day 3 post inoculation visualized by GFP-fluorescence (20-fold 
magnification), (B) RMS-13 control tumors (n=7) and RMS-13 LEF1 KD tumors (n=6) at day 7 post 
inoculation (10-fold magnification) and (C) RMS-13 LEF1 KD tumors and invading cells visualized by 
GFP-fluorescence (10-fold magnification; insets: 125-fold magnification). (D) Immunofluorescence staining 
of cryosections of RMS-13 LEF1 KD tumors with anti-HLA-A,B,C antibody (red) and DAPI (blue). White 
arrows mark tumor cells invading the stroma (s) and are enlarged in the insets (125-fold magnification). 




















6.7 Effect of LEF1 KD on the expression of muscle differentiation markers in RMS 
cell lines 
To investigate whether LEF1 affects myogenic differentiation of RMS cell lines, 
expression of the early muscle differentiation marker MYOD (Berkes et al., 2005) and the 
late muscle differentiation markers myosin heavy chain 1 (MYH1), DESMIN and muscle 
creatine kinase (CKM) (Owens, 1995; Novitch et al., 1996; Li et al., 1997; Iezzi et al., 
2002; Schiaffino et al., 2015) were analyzed by qRT-PCR.  
Since recent papers proposed an important role of β-catenin in myogenic differentiation of 
RMS cells (Singh, S. et al., 2010; Annavarapu et al., 2013), we also investigated if 
β-catenin is essential in this process. For this purpose, RMS control and LEF1 KD cell 
lines were transiently transfected with CTNNB1 specific siRNA and the successful 
β-catenin KD was verified for all cell lines by qRT-PCR (Figure 15, upper panel) and for 
RMS-13 and TE671 additionally by Western blot (Figure 15, lower panel). Hereby, 
β-catenin expression was reduced by more than 90 % on mRNA level and merely detected 
on protein level when compared to the respective control or LEF1 KD cells, which have 





Figure 15: β-catenin KD in human RMS cell lines. Upper panel qRT-PCR analysis of CTNNB1 in Rh41, 
RMS-13 and TE671 control and the respective LEF1 KD cells after transfection with scrambled (scr) 
siRNA (1) or CTNNB1 siRNA (2). Data represent two independent experiments performed in duplicates and 
measured in triplicates. Gene expression levels were normalized to 18S rRNA expression levels and data are 
displayed as mean+SEM; **P< 0.01, ***P< 0.001 by Students t-test. Lower panel Western blot analysis of 
β-catenin in RMS-13 and TE671 control and the respective LEF1 KD cells performed 96 h after transfection 
with scr siRNA (1) or CTNNB1 siRNA (2). β-Actin and HSC-70 served as loading control.  
 
As shown in Figure 16A, the LEF1 KD in Rh41 cells significantly increased MYH1 mRNA 
level but did not alter the expression of MYOD, DESMIN and CKM when compared to the 
values of control transduced cells that were set to 1. In contrast, RMS-13 LEF1 KD cells 
revealed an almost complete transcriptional suppression of all analyzed muscle 
differentiation markers compared to the respective control cells. In the ERMS cell line 
TE671, the LEF1 KD did not result in any significant changes regarding differentiation. 
The β-catenin KD significantly downregulated or upregulated the expression of MYH1 and 
DESMIN, respectively, in Rh41 LEF1 KD cells when compared to the scramble transfected 
LEF1 KD cells (Figure 16B). However, in all other settings the regulation of muscle 
differentiation markers was completely independent of the β-catenin KD.  














































Figure 16: LEF1-dependent expression of muscle differentiation markers in RMS cell 
lines.(A) Expression of MYOD, MYH1, DESMIN and CKM in Rh41 LEF1 KD, RMS-13 LEF1 KD and 
TE671 LEF1 KD cells are shown as fold change to the respective control cells that were set to 1 (dashed 
line). (B) Expression of the same markers in the same cells after transfection with scr or CTNNB1 siRNA. 
Indicated significances are shown for values after transfection with scr siRNA versus CTNNB1 siRNA. 
(A) and (B) Gene expression levels were normalized to 18S rRNA expression levels. Data represent 
mean+SEM of at least two independent experiments performed in duplicates and measured in triplicates; 






















































































































































































































































































To summarize, the LEF1 again provokes heterogeneous effects in the used RMS cell lines. 
Thus, LEF1 apparently is involved in a more differentiated phenotype of RMS-13 cells, 
whereas it promotes a less differentiated one in Rh41 cells (Figure 16A). In contrast, 
except a significant change in DESMIN and MYH1 mRNA levels in Rh41 LEF1 KD cells, 
β-catenin does not change the expression of muscle differentiation markers (Figure 16B). 
Together these data suggest that LEF1 is one of the major regulators of myodifferentiation 
in RMS and that β-catenin plays an inferior role in this process.  
6.8 WNT5A expression in primary human RMS  
After examining the interplay of LEF1 with WNT/β-catenin signaling, we next started to 
analyze whether LEF1 might interact with the β-catenin independent (non-canonical) WNT 
signaling in RMS. Thus, staining of the TMA of human RMS biopsies (see Chapter 6.1) 
with anti-WNT5A antibody revealed that WNT5A was highly expressed in all fusion-
positive ARMS and ERMS samples (Figure 17A). The studied samples could not be scored 
because the protein expression levels were very intense throughout the samples. This 
hampered the exact definition of cells that were negative, intermediately or intensely 
positive cells. Furthermore, the mRNA levels of WNT5A in the set of 10 human 
fusion-positive ARMS and 10 human ERMS samples were analyzed. As shown in Figure 
17B, WNT5A was also overexpressed on transcript level when compared to normal skeletal 
muscle (n=4). Moreover, the data showed that LEF1 mRNA levels positively correlate 
with that of WNT5A in ARMS, which just missed significance as estimated by Spearman 
correlation (Figure 17C). In contrast, the ERMS samples did not show any correlation 
(data not shown). 
To sum up, the data indicate that besides LEF1, also WNT5A might be involved in the 
pathogenesis of ARMS and ERMS. In addition, LEF1 and WNT5A expression might even 
correlate with each other in at least subtypes of ARMS. However, since WNT5A staining 
of the TMA was very strong, whereas WNT5A mRNA levels were only moderately 
elevated, the antigen retrieval conditions for WNT5A immunohistochemistry should be 
further optimized. Furthermore, LEF1 and WNT5A correlation has to be verified and 





Figure 17: Immunohistochemical and qRT-PCR analyses of WNT5A in human RMS biopsies. 
(A) Representative immunohistochemical staining of WNT5A of primary human RMS. Magnification 
200-fold. (B) WNT5A expression levels were analyzed by qRT-PCR in fresh-frozen biopsies of human 
fusion-positive ARMS (n=10) and human ERMS (n=10) compared to normal muscle (n=4). Gene expression 
levels were normalized to GAPDH expression levels. Bars, 95 % confidence intervals and mean values; 
*P<0.05, **P<0.01 by Mann-Whitney t-test. (C) Parametric Pearson and non-parametric Spearman 
correlation analyses of LEF1 with WNT5A expression levels in human fusion-positive ARMS biopsies. 
Regression line, 95 % confidence interval and correlation coefficient r for Pearson and Spearman test are 
given. 
 
6.9 Effect of LEF1 KD on WNT5A expression in RMS cell lines 
In parallel, we analyzed the effect of LEF1 KD on the expression of WNT5A in RMS cell 
lines. As shown in Figure 18, in RMS-13 LEF1 KD cells WNT5A mRNA levels were 
significantly downregulated when compared to control cells (that were set to 1). In 
contrast, LEF1 deletion in Rh41 and TE671 cells did not change the expression of WNT5A 
when compared to the respective control cells.  
This indicates that – similarly to some primary ARMS samples – LEF1 expression 
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Figure 18: LEF1-dependent modulation of WNT5A expression in RMS cell lines. qRT-PCR analysis of 
WNT5A in Rh41 LEF1 KD, RMS-13 LEF1 KD and TE671 LEF1 KD cells are shown as fold change to the 
respective control cells that were set to 1 (black bar). WNT5A expression levels were normalized to 18S 
rRNA expression levels. Data represent mean+SEM of three independent experiments performed in 
duplicates and measured in triplicates. ***P< 0.001 by Students t-test. 
 
6.10 Effect of LEF1 on WNT5A expression in RMS cell lines  
Since LEF1 expression also tends to positively correlate with WNT5A expression in 
primary human ARMS samples, we assumed that RMS-13 cells are an appropriate model 
to study the molecular basis of the observed LEF1/WNT5A interaction.  
First, the positive correlation of LEF1 and WNT5A was confirmed by Western blot 
analysis. As shown in Figure 19, the LEF1 KD in RMS-13 cells correlated with a 
remarkable decrease in WNT5A protein level when compared to control cells, which was 
in line with the mRNA data shown in Figure 18. In contrast, and similar to what was seen 
on mRNA level, WNT5A protein level upon LEF1 KD was slightly increased in 





















































































Figure 19: LEF1-dependent modulation of WNT5A protein level in ARMS cell lines. Western blot 
analysis of WNT5A in the ARMS cell lines RMS-13 and Rh41 stably transduced with empty vector control 
(control) or LEF1 shRNA (LEF1 KD). HSC-70 expression levels served as loading control. The data are 
representative of three independent experiments. 
 
Since WNT5A/WNT5A is significantly downregulated in RMS-13 LEF1 KD cells, we 
hypothesized that LEF1 is necessary for WNT5A expression. We also hypothesized that 
WNT5A signals back to the RMS cell lines in a para- or autocrine manner and fosters 
LEF1 expression in a positive feedback. This hypothesis is based on data from the 
literature. Thus, WNT5A signaling can activate PI3K-mediated AKT-phosphorylation 
(Zhang, S. et al., 2012; Zhao et al., 2015). Due to the fact that RMS frequently show 
phosphorylation of AKT (Cen et al., 2007) and since LEF1 can be upregulated by 
PI3K/AKT signaling (Huang et al., 2012), we so far have investigated whether i) LEF1 
expression was dependent on activation of this pathway and ii) the decrease of WNT5A 
levels upon deletion of LEF1 in RMS-13 cells was associated with inhibition of PI3K/AKT 
signaling.  
Indeed, phosphorylation of AKT was decreased in RMS-13 LEF1 KD cells when 
compared to the respective control transduced cells (Figure 20). This effect was not seen in 
Rh41 LEF1 KD cells, in which WNT5A/WNT5A expression is rather not modulated by 
LEF1.  












Figure 20: LEF1-dependent modulation of pAKT/AKT protein level in ARMS cell lines. Western blot 
analysis of pAKT/AKT in the ARMS cell lines RMS-13 and Rh41 stably transduced with empty vector 
control (control) or LEF1 shRNA (LEF1 KD). HSC-70 expression levels served as loading control. The data 
are representative of three independent experiments.  
 
In order to analyze whether LEF1 expression was dependent on activation of PI3K/AKT 
signaling, RMS-13 control cells were incubated with the dual PI3K/mTOR inhibitor PI103, 
the pure PI3K inhibitor GDC-0941 or the pure AKT inhibitor MK-2206 and LEF1 protein 
levels were analyzed by Western blot (Figure 21). Analysis of the phosphorylation status 
of AKT served as readout for PI3K/AKT activity.  
As shown in Figure 21, all inhibitors potently inhibited the phosphorylation of AKT when 
compared to the solvent. Moreover, the incubation of RMS-13 control cells with PI103 and 
GDC-0941 markedly decreased LEF1 protein levels when compared to the solvent treated 
cells. In contrast, LEF1 protein levels almost remained unaffected after incubation with 
MK-2206 compared to solvent.  
Together, these data indicate that in RMS-13 cells, PI3K signaling results in upregulation 










Figure 21: Effect of PI3K/pAKT/mTOR inhibitors on LEF1 protein levels in RMS-13. Western blot 
analysis of RMS-13 control cells incubated for 48 h with 3 µM PI103, 10 µM GDC-0941 or 1 µM MK-2206 
in comparison to untreated (ut) or solvent (solv) treated cells. β-Actin and HSC-70 expression levels served 














Until now only few data on the role of WNT signaling in RMS have been published and 
are restricted to β-catenin dependent (canonical) WNT signaling. These data suggest that 
canonical WNT signaling is functionally active in RMS cell lines and that activation of this 
pathway is associated with a more differentiated phenotype in ARMS as well as in ERMS 
and inhibited proliferation in ARMS (Singh, S. et al., 2010; Annavarapu et al., 2013). 
Thus, these findings support a potential tumor suppressive role of canonical WNT 
signaling in RMS that additionally promotes myogenic differentiation. The authors also 
propose that canonical WNT signaling might be a potential therapeutic target in the combat 
against RMS, in particular for patients with ARMS who currently have a poor outcome 
with limited therapeutic options (Annavarapu et al., 2013). Indeed, several studies suggest 
that canonical WNT pathway activity can inhibit cancer progression and predicts a better 
prognosis for a broad variety of solid tumor entities. Thus, elevated levels of nuclear 
β-catenin correlate with improved patient outcome in medulloblastoma, malignant 
melanoma, ovarian cancer and prostate cancer (Gamallo et al., 1999; Ellison et al., 2005; 
Horvath et al., 2005; Chien et al., 2009; Anastas et al., 2013). On the other hand, nuclear 
β-catenin accumulation and therefore activity of canonical WNT signaling is frequently 
involved in the development of tumors including colorectal, prostate and lung cancer 
(reviewed in Heuberger et al., 2010; Anastas et al., 2013). This reveals that in dependency 
on the cellular context canonical WNT signaling activity can either have a tumor 
suppressive or an oncogenic function. 
Likewise, the interaction partner of β-catenin, LEF1 can function as either an oncogene or 
a tumor suppressor in different cellular contexts. Consequently its activity can be both, 
positively and negatively correlated with patient outcomes in different types of cancer. For 
instance, the fact that transplantation of bone marrow cells overexpressing LEF1 leads to 
acute myeloid leukemia and B-precursor ALL in mice argues for a role as an oncogene 
(Petropoulos et al., 2008). However, LEF1 can also act as a tumor suppressor due to 
transcriptional repression of c-MYC. This has been found in a subset of T-ALL cases, in 
which LEF1 inactivation showed increased levels of c-MYC expression, which might be an 
important step in the molecular pathogenesis of T-ALL (Gutierrez et al., 2010).  
The aim of this thesis was to elucidate the role of LEF1 in RMS in more depth and to shed 





7.1 Wnt3a-driven β-catenin dependent (canonical) WNT signaling seems to play a 
subordinate role in RMS 
The TMA analysis revealed that 21 out of 48 primary human RMS samples express LEF1, 
which was exclusively found in the nucleus (Figure 3A). Thereby the number of LEF1 
positive cells and the intensity of LEF1 signals were higher in the less aggressive ERMS 
subtype compared to ARMS. Consistent with the results of the TMA, qRT-PCR analysis in 
fresh-frozen human fusion-positive ARMS and ERMS samples revealed heterogeneous 
LEF1 overexpression when compared to normal skeletal muscle (Figure 4A). Likewise, 
21 out of 48 primary human RMS samples of the TMA were positive for β-catenin but no 
correlation between LEF1 and β-catenin protein levels was observed (Figure 3B). 
However, nuclear β-catenin expression was only detected in one ERMS. This is in line 
with previously published data, in which approximately 24 out of 44 human ARMS and 
ERMS biopsies showed membranous/cytoplasmatic β-catenin expression, whereas nuclear 
expression was only seen in two cases of ERMS (Annavarapu et al., 2013). Similarly, the 
study by Shukla et al. revealed β-catenin mutations in two out of 60 ERMS samples that 
could be responsible for nuclear β-catenin accumulation (Shukla et al., 2012). The very 
low number of RMS showing nuclear β-catenin is also in agreement with studies by 
Bouron-Dal Soglio and colleagues, who did not find activating β-catenin mutations in their 
patient cohort (Bouron-Dal Soglio et al., 2009). Moreover, in our collection of human 
ARMS and ERMS samples, the expression of the major downstream target of canonical 
WNT signaling AXIN2 was rather downregulated compared to normal muscle (Figure 4C). 
Together, these data suggest that canonical WNT signaling is not active in most RMS, 
despite of sometimes high levels of LEF1/LEF1.  
The lack of canonical WNT signaling activity in primary human ARMS samples and 
activity in only few ERMS samples is also in line with our cell culture experiments using 
Wnt3a. The cell culture experiments suggest that activation of WNT/β-catenin signaling is 
only possible in subsets of RMS, such as specific ERMS subtypes. Hence, TOP/FOP 
reporter assay and immunofluorescence staining in RMS cell lines revealed that activation 
of canonical WNT signaling by Wnt3a (as shown by AXIN2 upregulation; Figure 7) 
induced neither TOP activity nor nuclear translocation of β-catenin in the ARMS cell lines 
Rh41 and RMS-13 (Figure 8 and Figure 11). In contrast, the ERMS cell line TE671 
showed strong luciferase induction and predominant nuclear accumulation of β-catenin in 




functional activation of the canonical WNT signaling in the human ERMS cell line RD18 
(Annavarapu et al., 2013). On the other hand, they also showed that this pathway is 
functionally active in the ARMS cell line Rh30. This is in contrast to our data, because the 
ARMS cell line RMS-13 (which was used in our study) is sometimes thought to be related 
to Rh30 and perhaps derived from the same patient tumor as Rh30. However, the origin of 
RMS-13 and Rh30 is not completely clear (reviewed in Hinson et al., 2013). Therefore, the 
differences between the studies may reflect heterogeneity of different RMS cell clones. 
Likewise, the observed differences between the cell lines might also depend on the 
histology of the individual tumor part that has been used for establishment of the individual 
cell line.  
Moreover, the lack of TOP reporter activity and common absence of nuclear -catenin 
after Wnt3a treatment in ARMS cells also suggest that Rh41 and RMS-13 cells may 
i) have a mutation in the endogenous β-catenin that prevents induction of Wnt3a-mediated 
signaling activity or ii) possess a mechanism, which retains endogenous β-catenin in the 
cytoplasm or at the plasma membrane and thus impedes its nuclear translocation 
(Kimelman et al., 2006). Importantly, we found no -catenin mutations in any of the RMS 
cell lines examined (data not shown). Thus, these results indicate that -catenin is 
functional and suggest the existence of mechanism(s) specific for ARMS, in which 
endogenous -catenin is rather hold back at the plasma membrane/cytoplasm. In fact, 
several studies indicate that cadherins and other catenins i.e. α-catenin or p120 catenin can 
sequester β-catenin at the cell membrane in order to mediate cell-cell adhesion. This can 
largely affect the signaling capacity of β-catenin (reviewed in McEwen et al., 2012; 
McCrea et al., 2015). Indeed, our immunofluorescence staining are in favor of a much 
stronger β-catenin staining at the cell membrane between adjacent ARMS cells, especially 
in Rh41, than in the ERMS cells (see Figure 11). The same observation has been made in a 
study, in which the expression and localization of cadherins and catenins in five ERMS 
and four ARMS cell lines was examined. Thus, ARMS cell lines showed generally 
stronger expression of N-cadherin and M-cadherin when compared to ERMS cell lines. In 
addition, immunofluorescence staining revealed that cadherins and catenins including 
β-catenin were barely detectable at intercellular contacts of ERMS cells, whereas in ARMS 
cells specific persistent localization was observed at the sites of cell-to-cell contact 
(Charrasse et al., 2004). Hence, it is tempting to speculate that the increased interaction of 




reduction of the cytosolic β-catenin pool and thus could prevent nuclear translocation of 
β-catenin in Rh41 and RMS-13. This is different in ERMS cells i.e. in TE671 cells, in 
which low cadherin expression and missing localization of cadherin/catenin at the sites of 
cell-to-cell contact results in nuclear translocation of cytoplasmatic β-catenin, where it can 
activate canonical WNT signaling in response to Wnt3a. However, this hypothesis remains 
to be elucidated in the future.  
Although canonical WNT signaling is not functionally active in the ARMS cell lines, 
AXIN2 was significantly upregulated in response to Wnt3a (Figure 7). Thus, expression of 
AXIN2 must be regulated by other factors independently of -catenin. Indeed, studies 
reported that E2F1, a transcription factor involved in cell cycle regulation and synthesis of 
DNA, can induce AXIN2 expression (Hughes et al., 2005; reviewed in Poppy Roworth et 
al., 2015). Likewise, the caudal-related homeobox transcription factor 2 (CDX2) has been 
shown to stimulate AXIN2 expression in colon cancer cell lines (Olsen et al., 2013). 
Moreover, expression of both transcription factors can be induced in response to Wnt3a 
(Khan et al., 2007; Sherwood et al., 2012).  
However, the fact that AXIN2 activation was not expressed in primary RMS samples (but 
in all cell lines upon Wnt3a treatment) argues for a minor role of WNT3A in the 
pathogenesis of RMS. 
This assumption was confirmed by an in vivo approach when heterozygous Ptch
del/+ 
mutants were crossed with Wnt
vt/vt
 mice. The vt
 
mutation is a naturally occurring 
hypomorphic mutation of Wnt3a, which decreases the level of Wnt3a expression and 
abrogates tail formation in homozygous mice (Greco et al., 1996). Wnt3a is a major 
activator of WNT/β-catenin dependent signaling. Since Wnt3a is expressed during the 
period of initial somite development and is essential for mesoderm and myotome formation 
(Ikeya et al., 1998; reviewed in von Maltzahn et al., 2012), we reasoned that Wnt
vt/vt
 mice 
represent a valuable model for attenuation of Wnt3a-driven canonical Wnt signaling during 





mice was similar to that of the control mice (Table 22 and Figure 5) (Nitzki 
et al., 2016). Furthermore, growth characteristics of RMS in vivo were also not affected by 
a heterozygous inactivating β-catenin mutation (Nitzki et al., 2016). Altogether, this 
indicates that Wnt3a/β-catenin-driven Wnt signaling plays a subordinate role in RMS 




possible that other upregulated Wnt ligands such as Wnt4, that can activate canonical Wnt 
signaling and regulate the myogenic fate of somites (Bernardi et al., 2011), might 





However, the lack of AXIN2 expression in primary RMS samples rather argues against 
such a scenario. 
The minor role of canonical WNT signaling in RMS is further fostered by the results of the 
TOP/FOP reporter assay. This assay revealed that the tumor suppressive function of LEF1 
does not require activation of β-catenin driven WNT signaling (Figure 10). Since LEF1 is 
expressed in primary human RMS samples, it can be speculated that LEF1 exerts functions 
in RMS that are independent of β-catenin activity. Indeed, β-catenin independent LEF1 
functions are well known and examples encompass interaction with ATF2 factors 
(Grumolato et al., 2013) and with the intracellular domain of Notch (Ross et al., 2001). 
This is also in line with our data, showing that the LEF1-induced effects on myogenic 
differentiation are mostly independent of β-catenin in all RMS cell lines. Thus, except a 
β-catenin-mediated up- or downregulation of DESMIN and MYH1, respectively, in 
Rh41 LEF1 KD cells, the β-catenin KD itself did not change the expression of muscle 
differentiation markers in RMS LEF1 KD cells (Figure 16B). Likewise, experiments in 
presomitic mesoderm explants revealed that MyoD and Myf5 expression can be activated 
by Pax3 despite the absence of functional β-catenin (Brunelli et al., 2007).  
In summary, β-catenin mediated WNT signaling seems to play a subordinate role in RMS 
and thus the LEF1-mediated effects are independent of this pathway, at least in a subset of 
RMS. 
However, in contrast to canonical WNT signaling, we have strong evidence that 
non-canonical WNT signaling might play a role in RMS. The first hint came from a 
genetic approach, in which Ptch
del/+ 
mutants were bred to Wif1
-/-
 mice. The latter do not 
express the Wnt inhibitory factor 1, which encodes an endogenous secreted Wnt pathway 
antagonist. In these mice RMS multiplicity was significantly decreased upon Wif1 deletion. 









 mice with multiple RMS significantly decreased to 11 % 
(Nitzki et al., 2016). Together with the fact that canonical Wnt signaling activity does not 
play a prominent role in RMS pathogenesis, these data strongly suggest that Wnts involved 




Wnt11 (Surmann-Schmitt et al., 2009) might restrain RMS formation, at least in mice. 
This part will be discussed in Chapter 7.3. 
7.2 LEF1 can reduce tumor progression and can induce myodifferentiation in a 
subset of RMS  
In order to analyze the function of LEF1 in RMS in detail, we established a stable 
LEF1 KD in the ARMS cell lines Rh41 and RMS-13 and in the ERMS cell line TE671. 
Hence, stable deletion of LEF1 resulted in a significant downregulation of the canonical 
WNT target AXIN2 in RMS-13 cells but not in Rh41 LEF1 KD or TE671 LEF1 KD cells 
(Figure 6B). In contrast, c-MYC was significantly increased in both ARMS cell lines upon 
LEF1 KD (Figure 6B). This is similar to T-cell acute lymphoblastic leukemia, in which 
LEF1-inactivated cases show increased levels of MYC expression when compared with 
cases with intact LEF1 (Gutierrez et al., 2010). Moreover, pro-B cells from Lef1-deficient 
mice revealed elevated levels of c-Myc (Reya et al., 2000). As shown in Figure 12, the 
LEF1 KD in RMS-13 was also accompanied by a significant decrease of all TCF factors 
when compared to control cells, which could explain the above mentioned downregulation 
of AXIN2 in this cell line upon LEF1 depletion (Figure 6B). 
Most importantly, our experiments revealed that LEF1 can restrain RMS aggressiveness. 
Thus, depending on the used cell line, LEF1 can i) induce apoptotic signals, ii) suppress 
proliferation, migration and invasiveness of RMS cells in vitro and in vivo and iii) can 
positively influence the myogenic differentiation status of the tumor cells (Figure 13, 
Figure 14 and Figure 16A).  
The anti-proliferative effect of LEF1 in the ARMS cell lines Rh41 and RMS-13 may be 
related to attenuation of c-MYC expression (Figure 6B). Although the role of c-MYC in 
ARMS has never been studied in detail, this assumption would be in line with the 
observation that c-MYC can foster migration, invasion and tumor-induced angiogenesis of 
ERMS (Bernard et al., 2006; Marampon et al., 2006). More precisely, growth of the 
ERMS cell line RD was arrested after stably over-expression of MadMyc chimera that 
specifically blocks c-MYC activity. Furthermore, functional inactivation of c-MYC can 
induce myogenic differentiation of the ERMS cell line RD (Marampon et al., 2006). Thus, 
it could be possible that the increased c-MYC levels in RMS-13 LEF1 KD cells are 





It is also possible that TCF1, TCF3 and TCF4 are associated with the LEF1-mediated RMS 
phenotype. Thus, while LEF1 KD in RMS-13 induces invasiveness, the opposite is the 
case for Rh41 cells where invasion is reduced (Figure 13). This was accompanied with a 
down- or upregulation of all TCFs, respectively (Figure 12). In TE671, neither TCF levels 
nor invasive capacity were remarkably affected (Figure 12 and Figure 13). This indicates 
that the dosage and/or composition of LEF1/TCF factors may regulate the invasiveness of 
RMS cells. 
Since LEF1/TCFs play a key role in the regulation of canonical WNT signaling activity 
and several studies suggest that TCFs can contribute to both activation and also to 
repression of WNT target genes, the regulation of TCF factors by LEF1 opens a very 
interesting perspective in RMS. TCF3 is generally known as a repressor of WNT target 
genes and the full-length, β-catenin-binding form of TCF4 is also sometimes associated 
with target gene repression but can also act as transcriptional activator (Tang et al., 2008; 
Cadigan et al., 2012; Shah et al., 2015). In contrast, full-length TCF1 and LEF1 are more 
often linked to WNT target gene activation (reviewed in Cadigan et al., 2012). A concrete 
mechanism, in which LEF1 directly mediates the regulation of TCF factors, is not known. 
Nevertheless, there is strong evidence that LEF1 negatively regulates IL-4 expression 
(independently of β-catenin), which in turn can inhibit TCF1/TCF1 expression levels 
(Hebenstreit et al., 2010; Maier et al., 2011). Moreover, incubation of RD and Rh30 cells 
with IL-4 resulted in decreased MYOD protein levels (Hosoyama et al., 2012). Thus, it can 
be speculated that RMS-13 cells possess a mechanism, in which LEF1 – e.g. via inhibition 
of IL-4 – can induce the expression of TCF factors and concomitantly myogenic 
differentiation.  
Together the data suggest that the function of LEF1 might involve regulation of TCFs, 
which again occurs in dependency on the cellular context. Thus, it is possible that TCFs 
may play a role in myogenic differentiation (and thus aggressiveness) modulated by LEF1, 
at least in ARMS cell lines. Indeed, recently it has been shown that TCF4 overexpression 
significantly up-regulated expression of MyoD and myosin heavy chain II proteins in 
mesenchymal stem cells (Singh, R. et al., 2009). In addition, LEF1 together with TCF1 has 
intrinsic HDAC activity, which is necessary for differentiation of CD8
+
 T-cells (Xing et 
al., 2016). In our settings, LEF1 induces the expression of TCF1 and TCF4 and of muscle 
lineage markers in RMS-13 cells (Figure 12 and Figure 16A). This is different in Rh41 




marker MYH1. It is also different in TE671 cells where LEF1 has no effect on TCF1, TCF4 
or muscle differentiation. Therefore it is tempting to speculate that there are subgroups of 
RMS, in which differentiation (and concomitantly aggressiveness) is either epigenetically 
regulated by LEF1 or by LEF1-mediated modulation of TCFs. The first hypothesis would 
be in line with a recent study that divides RMS into four distinct subtypes based on their 
genetic signature and DNA methylation pattern (Seki et al., 2015). However, the 
biological/genetic basis for a distinct epigenetic signature of RMS is currently unknown 
and should be addressed in the future.  
To sum up, the data suggest that LEF1 can counteract the aggressiveness of RMS and is 
probably one of the major mediators of RMS differentiation. However, the fact that LEF1 
fosters invasiveness and suppresses MYH1 expression in Rh41 cells indicate that this tumor 
suppressive function may be restrained to specific RMS subgroups.  
7.3 Interaction of LEF1 and WNT5A in RMS-13 cells  
Our analyses revealed that all primary human RMS samples of the TMA express WNT5A 
(Figure 17A). On transcript level, our collection of fresh-frozen ARMS and ERMS 
samples also overexpressed WNT5A when compared to normal muscle (Figure 17B). 
Despite the low number of analyzed samples, LEF1 expression apparently positively 
correlates with that of WNT5A in ARMS (Figure 17C). Since this may indicate a 
co-regulation of both factors, the expression of WNT5A in RMS LEF1 KD cell lines was 
studied. Indeed, a positive correlation of LEF1 and WNT5A was found in the ARMS cell 
line RMS-13. Thus, the LEF1 KD in RMS-13 resulted in downregulation of WNT5A on 
both mRNA and protein level (Figure 18 and Figure 19). Due to the fact that LEF1 rather 
has a tumor suppressive function in ARMS, we hypothesize that this also should hold true 
for WNT5A. In fact, WT5A can exert anti-tumorigenic functions such as inhibition of cell 
migration and invasiveness. As already described, WNT5A reduces the invasion of 
prostate cancer cells (Syed Khaja et al., 2011), and inhibits the migration of multiple breast 
cancer cell types (Säfholm et al., 2006; Hansen et al., 2009). Moreover, work from our 
own group support a role of WNT5A in regression and differentiation of basal cell 
carcinoma (Nitzki et al., 2010). In addition, WNT5A induces myogenic differentiation in 
mice and the expression of differentiation markers of colon cancer cells (Buttler et al., 




Hence, the data indicate that LEF1 might also regulate WNT5A, at least in a subset of 
ARMS. Taken together, we hypothesize that LEF1 can activate WNT5A and 
concomitantly inhibit the expression of c-MYC, which results in attenuation of 
aggressiveness of specific RMS subgroups.  
We next studied whether WNT5A activates PI3K/AKT signaling in RMS-13 cells. This 
was based on a literature review (Zhang, S. et al., 2012; Zhang et al., 2014), and due to the 
fact that RMS frequently show phosphorylation of AKT (Cen et al., 2007). Indeed, the 
decrease of WNT5A levels in RMS-13 LEF1 KD cells (see Figure 19) was associated with 
decreased levels of pAKT (Figure 20). Based on the fact that LEF1 expression itself can be 
induced by PI3K/AKT signaling (Huang et al., 2012), we next analyzed LEF1 protein 
levels in the parental RMS-13 cell line (without LEF1 KD) after incubation with the dual 
PI3K/mTOR inhibitor PI103, the pure PI3K inhibitor GDC-0941 or the pure AKT inhibitor 
MK-2206. Due to a remarkable decrease in LEF1 upon PI103 and GDC-0941 but not upon 
MK-2206 incubation (Figure 21), we conclude that LEF1 expression in RMS-13 is 
positively regulated by PI3K signaling in an AKT-independent manner. Indeed, although 
AKT is considered to be the key downstream effector of PI3K oncogenic signaling, several 
studies demonstrated that PI3K and AKT can act independently of each other in cancers 
(reviewed in Bruhn et al., 2013; Faes et al., 2015). Thus, AKT-independent signaling 
modes of PI3K in cancer include activation of RAC, which has been shown to regulate 
MEK/ERK signaling in breast cancer cells (Ebi et al., 2013). Besides RAC, mTORC2 
represents another kinase whose activation relies on PI3K and thus might be involved in 
AKT-independent effects of PI3K signaling. Although strong evidence emphasizes the 
importance of phosphorylation and activation of AKT by mTORC2, recent studies have 
revealed AKT-independent functions of mTORC2 in cancer (reviewed in Faes et al., 
2015). In addition, emerging evidence has shown the importance of serum- and 
glucocorticoid-inducible protein kinase 3 (SGK3) to be involved in AKT-independent 
PI3K signaling. SGK3 belongs to a family of kinases, which are highly homologous to the 
AKT family, sharing similar upstream activators and downstream targets and has been 
implicated in the regulation of cell growth, proliferation, survival and migration (reviewed 






Based on the already accomplished data and the literature review, we now propose a model 
for a subset of ARMS, in which LEF1 and WNT5A establish a positive feedback loop that 
counteracts the aggressiveness by inhibition of c-MYC (Figure 22). Since WNT5A can 
inhibit c-MYC expression via increase of intracellular Ca
2+
 (Kremenevskaja et al., 2005) 
and since vice versa c-MYC can repress WNT5A (Cappellen et al., 2007), the regulation 
of c-MYC expression in this model may also involve WNT5A. Moreover, the repression of 
c-MYC mediated by LEF1 and/or WNT5A could be responsible for the attenuation of 
aggressiveness (e.g. proliferation, migration and invasion). Whether this is true or not 
remains to be investigated in the future. 
 
Figure 22: Current model of the interplay of LEF1, WNT5A, PI3K and c-MYC in ARMS. (1) WNT5A 
signaling is responsible for PI3K activation, LEF1 expression and c-MYC repression. (2) Vice versa LEF1 
induces WNT5A expression either with or without the involvement of c-MYC. (3) WNT5A expression 
inhibits c-MYC expression. (4) WNT5A-and/or LEF1-associated c-MYC repression is responsible for 
attenuation of proliferation, migration and invasion of ARMS. Arrows and blocking signs in blue represent 
own data and in brown data provided by the literature. 
 
7.4 Outlook 
Analysis of primary RMS samples revealed a role of LEF1 but also non-canonical WNT 
signaling in the pathogenesis of this tumor. Based on the potential positive correlation of 
LEF1 and WNT5A expression in ARMS, the LEF1 knockdown experiments in RMS cell 

















propose a positive WNT5A – PI3K – LEF1 – WNT5A signaling loop and concomitant 
c-MYC repression at least in a subset of ARMS (Figure 22). To verify this assumption and 
to strengthen our model the following experiments should be performed. 
Does LEF1 induce WNT5A with or without involvement of c-MYC in RMS-13 cells? 
To verify whether LEF1 induces WNT5A via inhibition of c-MYC, c-MYC should be 
deleted in RMS-13 LEF1 KD cells by specific shRNA followed by WNT5A expression 
analysis. If the c-MYC KD results in WNT5A upregulation, a c-MYC-mediated WNT5A 
repression is very likely. If this is not the case, LEF1 stimulates WNT5A expression in a 
c-MYC-independent way. Consequently, it would be useful to find possible mediator 
proteins, which could be identified by transcriptome analysis of RMS-13 LEF1 KD cells in 
comparison to control cells.  
Does WNT5A activate PI3K and is this involved in regulation of LEF1 expression and 
attenuation of aggressiveness of RMS-13 cells? 
In order to prove that WNT5A activates PI3K signaling activity, RMS-13 cells should be 
incubated with recombinant WNT5A. Then the PI3K activation status and AKT 
phosphorylation should be measured i.e. by a PI3K activation assay or Western blot, 
respectively. The same analyses should be done in RMS-13 cells in which WNT5A is 
stably deleted.  
In order to show whether c-MYC is mainly inhibited by WNT5A or LEF1, 
RMS-13 LEF1 KD cells that do not express LEF1 or WNT5A should be incubated with 
recombinant WNT5A followed by c-MYC expression analysis. 
Furthermore, cellular effects such as proliferation, apoptosis, migratory and invasive 
properties as well as the expression of muscle differentiation markers should be analyzed 
in RMS-13 LEF1 KD after treatment with recombinant WNT5A. This could clarify 
whether WNT5A influences aggressiveness of RMS-13 cells in a LEF1-independent 
manner. 
Is LEF1 upregulated by PI3K in an AKT independent manner? 
In order to analyze whether PI3K is involved in LEF1 expression, PI3K activity in 
RMS-13 cells should be modulated by overexpression of a constitutively active PI3K 
isoform or inhibition of PI3K using siRNA technology. Afterwards, LEF1 and c-MYC 




Is c-MYC repression involved in proliferation, migration and invasion in ARMS? 
In ERMS cells it has been demonstrated that c-MYC affects proliferation, migration, 
invasion and tumor-induced angiogenesis (Marampon et al., 2006; Gravina et al., 2016). 
However, in ARMS this has not yet been analyzed. Therefore, ARMS cell lines with a 
stable c-MYC KD should be established (i.e. in RMS-13 and Rh41 cells). Afterwards, the 
RMS-13 c-MYC KD and the respective control cells should be analyzed regarding 
apoptosis, proliferation, migration and invasion as described in this thesis. This will show 
whether repression of c-MYC is responsible for a less aggressive phenotype in RMS-13 
cells. 
Does WNT5A activate WNT/Ca
2+
 and/or WNT/JNK signaling? 
WNT5A activates the WNT/Ca
2+
 signaling pathway in the presence of receptor FZD2, 3, 
4, 6, and 5 that interact with the participating co-receptor ROR1/2 (He et al., 1997; 
Slusarski et al., 1997; Kühl et al., 2000; Weeraratna et al., 2002). Binding of WNT5A to 
ROR2 can also activate the WNT/JNK pathway (Oishi et al., 2003). Furthermore, it has 
been shown that Ca
2+
/CAMKII can activate PI3K (Joyal et al., 1997). In order to see, 
which pathway is potentially activated by WNT5A and modulates LEF1 and c-MYC 
expression or PI3K activity, the RMS-13 cells could be treated with specific inhibitors of 
the WNT/JNK and WNT/Ca
2+
 pathways (e.g. JNK or CAMKII inhibitors; Zhang, T. et al., 
2012; Pellicena et al., 2014). Then the expression of LEF1 and c-MYC and the PI3K 
activity should be analyzed. Also the activation status of WNT/JNK and 
WNT/Ca
2+
 signaling should be determined by analysis of the phosphorylation status of 
JNK and c-Jun or PKC and CaMKII, respectively.  
Is Lef1/Wnt5a associated with a more aggressive RMS phenotype in mice? 
In addition, in vivo studies would help to ascertain if LEF1 and/or WNT5A can induce a 
less aggressive RMS phenotype. For this purpose, Lef1 or Wnt5a could be conditionally 
inactivated in RMS of Ptch
del+
 mice. To analyze whether Lef1 or Wnt5a are involved in 
RMS formation, the knockout of Lef1 and Wnt5a can be induced in 4-weeks old mice 
followed by RMS monitoring. In order to analyze the role of these genes in RMS 
progression, the knockout could be induced in fully-developed RMS. Tumor growth could 
be monitored by volumetric computer tomography. Afterwards, isolated tumors should be 
analyzed by qRT-PCR, Western blot, histological and immunohistochemical staining e.g. 
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